var title_f23_40_24192="Gingivitis child";
var content_f23_40_24192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingivitis in a 14-year-old child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plaque deposits are clearly visible on the teeth at the gingival margin. Erythematous and edematous areas can be seen along the gingival margin. Particularly severe gingivitis with a trace of spontaneous bleeding is seen around the erupting upper left canine tooth. This is due to inadequate plaque removal secondary to malposition and crowding, and to the inflammation associated with eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Griffen, DDS, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24192=[""].join("\n");
var outline_f23_40_24192=null;
var title_f23_40_24193="Calculator: Glomerular filtration rate estimate by Schwartz formula";
var content_f23_40_24193=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"GFR_Schwartz_form\" name=\"GFR_Schwartz_form\" onkeydown=\"clrResults();\" onkeyup=\"GFR_Schwartz_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Glomerular filtration rate estimate by Schwartz formula",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          GlomerularFiltrationRate = MuscleFactor * Height / SerumCreat",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Creat_param\" onblur=\"GFR_Schwartz_fx(); minMaxCheck();\" onchange=\"GFR_Schwartz_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Creat_unit\" onchange=\"GFR_Schwartz_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0113122171945701|0|mcmol/L_Cr\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1|0|mg%_Cr\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Cr\">",
"               mg/dL",
"              </option>",
"              <option value=\"11.3122171945701|0|mmol/L_Cr\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"GFR_Schwartz_fx(); minMaxCheck();\" onchange=\"GFR_Schwartz_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"GFR_Schwartz_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Muscle Factor",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Muscle_Factor_radio\" onclick=\"GFR_Schwartz_fx();\" type=\"radio\" value=\"Premature infant up to 1 year of age|0.33\"/>",
"              Premature infant up to 1 year of age (0.33)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Muscle_Factor_radio\" onclick=\"GFR_Schwartz_fx();\" type=\"radio\" value=\"Term infant up to 1 year of age 1|0.45\"/>",
"              Term infant up to 1 year of age 1 (0.45)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Muscle_Factor_radio\" onclick=\"GFR_Schwartz_fx();\" type=\"radio\" value=\" Child or adolescent girl|0.55\"/>",
"              Child or adolescent girl (0.55)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Muscle_Factor_radio\" onclick=\"GFR_Schwartz_fx();\" type=\"radio\" value=\"Adolescent boy|0.7\"/>",
"              Adolescent boy (0.7)",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Glomerular Filtration Rate",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Glomerular_Filtration_Rate_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                mL/min/1.73 m",
"                <sup>",
"                 2",
"                </sup>",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      The",
"      <b>",
"       Muscle Factor",
"      </b>",
"      is directly proportional to the muscle component of the body and varies with the",
"age of the infant or child.",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      Muscle Factor",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g.  (0.33), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life.",
"        <i>",
"         J Pediatr",
"        </i>",
"        . 1984 Jun;104(6):849-54.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys.",
"        <i>",
"         J Pediatr",
"        </i>",
"        . 1985 Mar;106(3):522-6.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24193=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function GFR_Schwartz_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.GFR_Schwartz_form){",
"",
"",
"doCalc = true;",
"if (Serum_Creat_param.value.indexOf(',') >= 0){ Serum_Creat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Creat_unit.options[Serum_Creat_unit.selectedIndex].value.split('|');",
"Serum_Creat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Muscle_Factor_radio[0].checked){ Muscle_Factor = 0.33; }",
"if (Muscle_Factor_radio[1].checked){ Muscle_Factor = 0.45; }",
"if (Muscle_Factor_radio[2].checked){ Muscle_Factor = 0.55; }",
"if (Muscle_Factor_radio[3].checked){ Muscle_Factor = 0.7; }",
"dp = 1;",
"Glomerular_Filtration_Rate =  Muscle_Factor * Height / Serum_Creat;",
"",
"if (doCalc) Glomerular_Filtration_Rate_param.value = fixDP(Glomerular_Filtration_Rate, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GFR_Schwartz_form){",
"",
"if (Height_param.value && Height < 0) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 0 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 275) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 275 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GFR_Schwartz_form){",
"",
"Glomerular_Filtration_Rate_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f23_40_24193=null;
var title_f23_40_24194="Patient information: Leukemia in children (The Basics)";
var content_f23_40_24194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/15/15602\">",
"         Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/4/14402\">",
"         Patient information: Acute myeloid leukemia (AML) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/13/38098\">",
"         Patient information: Leukemia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/7/18546\">",
"         Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Leukemia in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/leukemia-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13207501\">",
"      <span class=\"h1\">",
"       What is leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leukemia is another word for cancer of the blood. The blood is made up of different types of cells. These cells are made in the middle of bones, in a part called the bone marrow.",
"     </p>",
"     <p>",
"      In leukemia, the bone marrow makes abnormal blood cells instead of normal blood cells. The abnormal cells grow out of control, get into the blood, and travel around the body. Sometimes, these cells collect in certain parts of the body. When the bone marrow makes abnormal blood cells, it does not make the normal blood cells your child&rsquo;s body needs. This causes symptoms.",
"     </p>",
"     <p>",
"      There are different types of leukemia. Some types grow quickly, and others grow slowly. Most leukemia in children is the fast-growing type, called &ldquo;acute&rdquo; leukemia. There are 2 types of acute leukemia. Most leukemia in children is acute lymphoblastic leukemia, also called &ldquo;ALL.&rdquo; Some leukemia in children is acute myeloid leukemia, also called &ldquo;AML.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207516\">",
"      <span class=\"h1\">",
"       What are the symptoms of leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling very tired and weak",
"       </li>",
"       <li>",
"        Bleeding more easily than usual",
"       </li>",
"       <li>",
"        Getting fevers or infections more easily than usual",
"       </li>",
"       <li>",
"        Bone pain, which can make children limp or refuse to walk",
"       </li>",
"       <li>",
"        Swollen lymph nodes (bean-shaped organs) that you can see or feel under your child&rsquo;s skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not leukemia. But if your child has these symptoms, let the doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207531\">",
"      <span class=\"h1\">",
"       Is there a test for leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your child&rsquo;s symptoms and do an exam. He or she will also do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A bone marrow biopsy &ndash; For this test, a doctor takes a very small sample of the bone marrow. Then another doctor looks at the cells under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207546\">",
"      <span class=\"h1\">",
"       How is leukemia in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment for your child will depend on the type of leukemia he or she has. Treatment for leukemia can include 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Children usually get these medicines through a thin tube that goes in their vein. Sometimes, children also get these medicines through a thin tube that goes in their back.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        Bone marrow transplant &ndash; This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation. The &ldquo;donor&rdquo; cells can come from different places, including:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        People who are related to your child, and whose blood matches your child&rsquo;s",
"       </li>",
"       <li>",
"        People who are not related to your child, but whose blood matches your child&rsquo;s",
"       </li>",
"       <li>",
"        Blood (that matches your child&rsquo;s) from a newborn baby&rsquo;s umbilical cord",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most children are in &ldquo;remission&rdquo; after they start treatment. This means that doctors do not see any more abnormal blood cells in the blood or bone marrow. But even though doctors do not see any abnormal cells, they are still in the body. To kill these cells and keep the leukemia from returning, your child will need to finish treatment. It usually takes about 2 to 3 years to finish treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207561\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, the doctor will check your child every so often to see if the leukemia comes back. Follow-ups include talking with the doctor, exams, and blood tests. Sometimes, the doctor will also do a bone marrow biopsy.",
"     </p>",
"     <p>",
"      You should also watch your child for the symptoms listed above. Having those symptoms could mean the leukemia has come back. Tell the doctor or nurse if your child has any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207576\">",
"      <span class=\"h1\">",
"       What happens if the leukemia comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the leukemia comes back, your child might have more chemotherapy, radiation, or a bone marrow transplant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207591\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all of the doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to let the doctor know if your child has any side effects or problems during treatment.",
"     </p>",
"     <p>",
"      Leukemia treatment can involve making many choices, such as what treatment your child should have and when. Always let the doctors and nurses know how you feel about a treatment. Any time your child is offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help my child live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if my child does not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207606\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       Patient information: Leukemia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=see_link\">",
"       Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=see_link\">",
"       Patient information: Acute myeloid leukemia (AML) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18546?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/40/24194?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83252 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.17-F31196724F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24194=[""].join("\n");
var outline_f23_40_24194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207501\">",
"      What is leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207516\">",
"      What are the symptoms of leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207531\">",
"      Is there a test for leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207546\">",
"      How is leukemia in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207561\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207576\">",
"      What happens if the leukemia comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207591\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207606\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18546?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_40_24195="Hepatic NRH light low";
var content_f23_40_24195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular regenerative hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This low power (4x) view of a liver biopsy with a reticulin stain shows a vague nodular pattern. The aggregation of hepatocytes with abundant cytoplasm surrounded by narrow sheaths of compressed cells gives the liver a nodular appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Matthew Turner, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24195=[""].join("\n");
var outline_f23_40_24195=null;
var title_f23_40_24196="Crohn's disease";
var content_f23_40_24196=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Crohn's disease (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/40/24196/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24196/contributors\" id=\"au6616\">",
"       Mark A Peppercorn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/40/24196/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24196/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/40/24196/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24196/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?23/40/24196?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Crohn's disease is a condition that affects the digestive tract. The cause of Crohn's disease is unknown. The most common symptoms of Crohn's disease include diarrhea, abdominal pain, weight loss, and fever. Some people with Crohn's disease also have problems outside of the digestive tract, including a skin rash, joint pain, eye redness, and, less commonly, liver problems.",
"    </p>",
"    <p>",
"     There is no cure for Crohn's disease, but there are medicines that can help to keep the disease under control. If medicine does not control symptoms, surgery might be an option to remove the diseased part of the colon.",
"    </p>",
"    <p>",
"     This article discusses the symptoms and treatment of Crohn's disease. More detailed information about Crohn's disease is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"      \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"      \"Surgical management of ulcerative colitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS CROHN'S DISEASE?",
"     </span>",
"    </p>",
"    <p>",
"     Crohn's disease is an autoimmune disease, but the precise cause is not known. Having family members with Crohn's disease probably increases the risk of developing the condition. When a person with this inherited risk is exposed to a trigger (an illness or something in the environment), the immune system is activated.",
"    </p>",
"    <p>",
"     In people with Crohn's disease, the immune system recognizes the lining of the digestive tract as foreign and attacks it, causing inflammation. This inflammation causes the lining of the digestive tract to develop ulcers and bleed. Crohn's disease usually affects the colon and ileum, but it can affect the entire digestive tract, from the mouth to the anus (",
"     <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Crohn's disease, like ulcerative colitis, is an inflammatory bowel disease (IBD). Inflammatory bowel disease should not be confused with irritable bowel syndrome (IBS). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Will I get better?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Crohn's disease usually follows a pattern of:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Flares (when the condition worsens)",
"      </li>",
"      <li>",
"       Remissions (when it improves)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     About 10 to 20 percent of people will have a remission after their first flare of Crohn's disease. The pattern can be variable, with repeated bouts (weeks to months) of symptoms, such as mild diarrhea and cramping. Less commonly, there can be severe and disabling symptoms (such as severe abdominal pain and a blockage in the bowels). Lifelong treatment is needed for people with Crohn's disease, and treatment increases the chance of entering and staying in remission.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CROHN'S DISEASE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of Crohn's disease include abdominal pain, diarrhea, fatigue, and weight loss. Other symptoms can include mouth sores, skin problems, eye inflammation, and anal problems, such as fistulas and abscesses.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mouth sores &ndash; Mouth sores (called aphthous stomatitis) can develop during flares of Crohn's disease. They are usually found between the gums and lower lip, or along the sides or underside of the tongue (",
"       <a class=\"graphic graphic_picture graphicRef80305 \" href=\"UTD.htm?25/51/26416\">",
"        picture 1",
"       </a>",
"       ). Mouth sores are often painful. The medicines used to treat the digestive tract usually help to treat mouth sores.",
"      </li>",
"      <li>",
"       Eye inflammation &ndash; Inflammation of the eyes (called uveitis or scleritis) occurs in up to 5 percent of people with Crohn's disease. These problems can affect one or both eyes. Symptoms of uveitis include \"floaters\" in the vision, eye pain, blurred vision, and sensitivity to light. Scleritis can cause burning or itching of the affected eye. Treatment usually includes eye drops. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"        \"Skin and eye manifestations of inflammatory bowel disease\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Anal problems &ndash; Crohn's disease can cause problems in the area around the anus. The most common problems include fissures (tears), ulcers, fistulas (a tunnel between the intestine and other organs), infected areas of skin, and stenosis (narrowing of the anus). These problems may occur alone or in combination. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"        \"Perianal complications of Crohn's disease\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Anal problems sometimes heal on their own without treatment. In other cases, treatment with medicines or surgery will be required. Soaking your bottom in warm water a few times a day and gently cleaning the area can help to speed healing.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CROHN'S DISEASE MEDICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of medicines used to treat Crohn's disease. The \"best\" medicine depends upon which part of the digestive tract is causing symptoms. The following is a summary of commonly used medications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"      \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      5-aminosalicylates",
"     </span>",
"     &nbsp;&mdash;&nbsp;The 5-aminosalicylates (abbreviated 5-ASA) are a group of medicines that reduce inflammation in the digestive tract. 5-ASA medicines are usually used first to treat a flare and may be recommended continuously to prevent new flares. Mesalamine (sold as Asacol&reg; and Pentasa&reg;) is the most commonly used 5-ASA. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"      \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;If 5-ASA medicines do not control your symptoms, your doctor or nurse may recommend a course of antibiotics. Antibiotics can reduce the number of bacteria in the intestines, which may help to reduce inflammation. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"      \"Antibiotics for treatment of inflammatory bowel diseases\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;A type of medicine called steroids (such as prednisone and budesonide) may be recommended if you do not respond to 5-ASAs or antibiotics, or if you have severe symptoms. Steroids are usually used for a limited time to get the inflammation under control, and are then slowly stopped. Steroids are not usually recommended long-term because of the risk of side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Immunomodulators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Immunomodulators help to reduce the inflammation associated with Crohn's disease. Immunomodulators might be recommended if you have severe symptoms or do not improve with steroids, or if your symptoms worsen after decreasing your steroid dose. The most commonly used immunomodulators include azathioprine, 6-mercaptopurine, and methotrexate. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"      \"Immunomodulator therapy in Crohn's disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Biologic response modifiers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Biologic response modifiers are a class of medicines that work by preventing inflammation. These medicines are often used in combination with treatments described above.",
"    </p>",
"    <p>",
"     Biologic response modifiers are costly and can have serious side effects (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Side effects'",
"     </a>",
"     below). As a result, biologic response modifiers are generally reserved for people with severe symptoms who have not responded to other treatments.",
"    </p>",
"    <p>",
"     All biologic response modifiers are given as an injection; some can be given at home, while others must be given in a doctor's office. The most commonly used biologic response modifiers include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Infliximab &ndash; Infliximab (Remicade&reg;)",
"      </li>",
"      <li>",
"       Adalimumab &ndash; Adalimumab (Humira&reg;)",
"      </li>",
"      <li>",
"       Certolizumab pegol &ndash; Certolizumab pegol (Cimzia&reg;)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Biologic response modifiers interfere with the immune system's ability to fight infection and should not be used in people with serious infections. Testing for tuberculosis (TB) is needed before starting treatment since treatment can \"activate\" TB if you have been exposed to TB previously. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"      \"Patient information: Tuberculosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Biologic response modifiers are not recommended for people who currently have or have previously had lymphoma (a type of cancer). Some studies have reported an association between these drugs and a higher risk of developing lymphoma. More research is needed in this area.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      SURGERY FOR CROHN'S DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     Medicines can help control the symptoms and complications of Crohn's disease and can help you to avoid or postpone surgery. However, surgery may be recommended if your symptoms are not controlled with medicine or if the side effects of medicine are unbearable. About 80 percent of people with Crohn's disease will need surgery at some point in their life. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"      \"Surgical management of ulcerative colitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is important to have realistic expectations of surgery. Surgery does not cure Crohn's disease, but it can help you to feel better and return to normal activities. The disease eventually returns after surgery, and most people will need to keep taking medicines to control symptoms over the long term. However, between 85 and 90 percent of people have no symptoms during the year following surgery. Up to 20 percent of people have no symptoms 15 years after surgery. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/809?source=see_link\">",
"      \"Medical prophylaxis of postoperative Crohn's disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The most commonly performed surgeries for Crohn's disease include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Removal of part of the colon &ndash; For this procedure, the surgeon removes the diseased part of the intestine (called a resection), then rejoins the two ends (called an anastomosis). After surgery, most people are still able to have bowel movements as usual, through the anus.",
"       <br/>",
"       <br/>",
"       In some cases, the surgeon will not be able to reconnect the two ends of the intestine. Instead, he or she will connect the intestines to an opening in the abdomen, called an ostomy (",
"       <a class=\"graphic graphic_figure graphicRef57774 \" href=\"UTD.htm?6/7/6256\">",
"        figure 2",
"       </a>",
"       ). Bodily waste will exit your body through the ostomy, rather than through your anus. You will wear a plastic bag on the outside of the ostomy to collect the waste, and you will empty the bag as needed.",
"       <br/>",
"       <br/>",
"       In most cases, the ostomy is temporary and is reversed after your colon has healed for a few months. In other cases, a permanent ostomy is required.",
"       <br/>",
"       <br/>",
"       The idea of an ostomy can be frightening. You will need to learn how to care for the ostomy, including how to care for the skin around the ostomy and fitting and emptying the bag that covers the ostomy. An ostomy nurse specialist is expert in the care of people with ostomies. With training, time, and support, it is possible to lead a normal life with an ostomy.",
"      </li>",
"      <li>",
"       Opening blockages &ndash; Strictureplasty is a procedure used to open blockages (strictures) in the bowel. It is sometimes done at the same time as a resection. Strictureplasty may be recommended if you have blockages in a particular part of your bowels over and over.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CROHN'S DISEASE AND LIFESTYLE",
"     </span>",
"    </p>",
"    <p>",
"     There might be certain foods or food groups that worsen your symptoms, particularly during flares, and it is reasonable to avoid these foods temporarily. However, eliminating entire food groups can lead to malnutrition. Talk to your doctor, nurse, or a dietitian for help in managing your diet.",
"    </p>",
"    <p>",
"     Other lifestyle recommendations include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Regular exercise is a good idea for everyone, including people with Crohn's disease",
"      </li>",
"      <li>",
"       Smoking can worsen Crohn's disease and increases the risk of needing surgery. People with Crohn's disease should not smoke. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Avoid taking nonsteroidal antiinflammatory drugs (such as ibuprofen (sold as Motrin&reg; and Advil&reg;) and naprosyn (sold as Aleve&reg;)) since they can worsen the disease.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Crohn's disease and colon cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having Crohn's disease increases your risk of developing colorectal cancer. Your risk depends on how long you have had Crohn's disease and how much of your colon is affected. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"      \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     To find colorectal cancer as soon as possible, most experts recommend that people with Crohn's disease start having colon cancer screening early and often. For some people, this might mean having a colonoscopy eight years after being diagnosed, and then once per year thereafter. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Talk to your doctor or nurse to find out when you should start having colon cancer screening and how often it should be repeated. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      PREGNANCY AND CROHN'S DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     Pregnancy and Crohn's disease are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=see_link\">",
"      \"Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     New medicines are continually being developed to treat Crohn's disease. The majority of the new medicines that are being developed help control inflammation. Many of these drugs are currently undergoing clinical trials. As of yet, none have been proven to be better than currently available treatments. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=see_link\">",
"      \"Investigational therapies in the medical management of Crohn's disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you are interested in participating in a clinical trial, discuss this with your doctor or nurse or read more about clinical trials on the Internet (",
"     <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"      www.clinicaltrials.gov/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498725059\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H185761404\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40882?source=see_link\">",
"      Patient information: Ileostomy care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/55/29554?source=see_link\">",
"      Patient information: Crohn&rsquo;s disease in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H185761412\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=see_link\">",
"      Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33829?source=see_link\">",
"      Certolizumab pegol for treatment of Crohn's disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=see_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/809?source=see_link\">",
"      Medical prophylaxis of postoperative Crohn's disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.digestive.niddk.nih.gov/ddiseases/pubs/crohns/index.htm\">",
"      www.digestive.niddk.nih.gov/ddiseases/pubs/crohns/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Crohn's and Colitis Foundation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ccfa.org/\">",
"      www.ccfa.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Crohn's Disease Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://ibdcrohns.about.com/forum\">",
"      file://ibdcrohns.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?23/40/24196/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?23/40/24196?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24196/abstract/1\">",
"      Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24196/abstract/2\">",
"      Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24196/abstract/3\">",
"      Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch Surg 2005; 140:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f23_40_24196=[""].join("\n");
var outline_f23_40_24196=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS CROHN'S DISEASE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CROHN'S DISEASE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CROHN'S DISEASE MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           SURGERY FOR CROHN'S DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CROHN'S DISEASE AND LIFESTYLE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           PREGNANCY AND CROHN'S DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\" title=\"figure 1\">",
"           Digestive system adult PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6256\" title=\"figure 2\">",
"           Colostomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/51/26416\" title=\"picture 1\">",
"           Oral aphthae PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f23_40_24197="Treatment of acute stress disorder";
var content_f23_40_24197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute stress disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24197/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24197/contributors\">",
"     Richard Bryant, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24197/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24197/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24197/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24197/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/40/24197/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21031615\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute stress disorder (ASD) is characterized by acute stress reactions that may occur in the initial month after a person is exposed to a traumatic event. The disorder includes dissociative, reexperiencing, avoidance, and arousal symptoms. Some patients who experience ASD go on to experience posttraumatic stress disorder (PTSD), which is diagnosed only after four weeks following exposure to trauma.",
"   </p>",
"   <p>",
"    Treatment for ASD, which is principally trauma-focused cognitive-behavioral therapy, is aimed at curtailing symptoms of acute stress responses and preventing their development into PTSD.",
"   </p>",
"   <p>",
"    The treatment of ASD is discussed here. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of ASD are discussed separately. The epidemiology, pathogenesis, clinical manifestations, course, diagnosis, and treatment of PTSD are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=see_link\">",
"     \"Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033141\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatment for acute stress disorder (ASD) is trauma-focused cognitive-behavioral therapy (CBT), which has been shown to reduce the likelihood of subsequently developing PTSD. Short-term use of a benzodiazepine may be useful for reducing acute arousal and sleep disturbance. Treatment of acute stress disorder is also addressed in trials of interventions to prevent PTSD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link&amp;anchor=H5614776#H5614776\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H19958403#H19958403\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A proportion of people with ASD will adapt without formal intervention (between one half to one quarter of people with ASD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033148\">",
"    <span class=\"h1\">",
"     COGNITIVE-BEHAVIORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma-focused cognitive-behavioral therapy (CBT) for acute stress disorder (ASD) typically includes patient education, cognitive restructuring, and exposure.",
"   </p>",
"   <p>",
"    Educating patients about posttraumatic reactions should aim to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normalize the stress response",
"     </li>",
"     <li>",
"      Heighten expectancy of recovery",
"     </li>",
"     <li>",
"      Explain the stress responses in terms of conditioning models that require the patient to learn that reminders are no longer dangerous. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cognitive restructuring is used to address maladaptive or unrealistic appraisals the patient may have about the trauma, his or her response to the event, and fears of potential future harm.",
"   </p>",
"   <p>",
"    Trauma-focused CBT for ASD optimally includes both imaginal exposure and in vivo exposure. In imaginal exposure, the patient provides a detailed narrative of his or her traumatic experience in which the patient orally relives the traumatic experience with the therapist (usually for at least 30 minutes), with the intention of achieving extinction learning. By reliving the memory repeatedly, the patient can learn that the salient reminder of the trauma (eg, the memory) is no longer a threat and does not result in aversive outcomes. Based on a similar mechanism, in vivo exposure is conducted to ensure that the patient is not avoiding feared situations in their daily life, thereby consolidating the learning that reminders are no longer signaling threat. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033155\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with ASD, we recommend early intervention with trauma-focused CBT that includes exposure treatment. For some patients treated for ASD, including patients with the features below, it is necessary to delay exposure therapy for several months into the PTSD phase:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extreme avoidance or dissociative responses, because these presentations may indicate extreme stress responses that may be complicated by exposure",
"     </li>",
"     <li>",
"      A primary response of anger, because anger often does not respond optimally to exposure exercises and may respond better to cognitive therapy",
"     </li>",
"     <li>",
"      An acute grief response, because exposure therapy may complicate normal grieving",
"     </li>",
"     <li>",
"      Borderline or psychotic features, because these people require containment and exposure may complicate their presentation",
"     </li>",
"     <li>",
"      Significant suicidal risk, because these patients require suicide management",
"     </li>",
"     <li>",
"      Persisting PTSD responses to childhood trauma, because addressing childhood trauma weeks after a recent trauma may be excessively difficult",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033163\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is typically delivered at least two weeks after trauma exposure. This allows the individual additional time for transient symptoms to abate and for post-trauma stressors to ease. The commencement of therapy should be timed with respect for other stressful events stemming from the trauma. The patient may find it difficult to focus attention on therapy if distracted by trauma-related events or experiences, such as pain, surgery, legal proceedings, relocation, or other stressors.",
"   </p>",
"   <p>",
"    CBT for ASD patients should typically be provided by a trained clinician over six weekly sessions of 60 to 90 minutes; additional sessions can be added if necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H1118664197#H1118664197\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Exposure therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033170\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of four trials of patients with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], treatment with trauma-focused CBT reduced ASD symptoms by the completion of treatment, and also reduced the proportion of participants who developed PTSD during the subsequent three to six months compared to supportive counseling (Relative Risk = 0.36 [95% CI 0.17 to 0.78]) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent trial found exposure treatment to be more effective than cognitive restructuring or a waitlist control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/7\">",
"     7",
"    </a>",
"    ]. The trial randomly assigned 90 individuals who experienced trauma and met diagnostic criteria for ASD to receive imaginal and in vivo exposure, cognitive restructuring, or to a waitlist control group. After six weeks of treatment, fewer patients in the exposure group met diagnostic criteria for PTSD as compared to those in the cognitive restructuring or waitlist groups. At six months, patients in the exposure group remained less likely to meet PTSD criteria, and were 2.8 times more likely to achieve remission of their initial symptoms than patients in the waitlist group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033178\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have not yielded sufficient evidence to determine the efficacy of medications for acutely traumatized individuals or those diagnosed with ASD; however, based on our clinical experience, we suggest short-term benzodiazepine treatment of patients with ASD and intense anxiety, agitation, or sleep disturbance in the immediate period following the traumatic event. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033185\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, nonrandomized trials of benzodiazepine treatment suggest that benzodiazepines may be helpful for acute anxiety, agitation, or sleep disturbance in the immediate period following the traumatic event in patients with ASD. Prolonged use may be detrimental to adaptation leading to higher rates of PTSD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small, uncontrolled trial described benzodiazepine treatment of four patients, within one to three weeks of trauma exposure, who had ASD symptoms that included disturbed sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"       Temazepam",
"      </a>",
"      30 mg was administered orally at bedtime for five days, followed by two days at 15 mg. The patients experienced improved sleep and reduced ASD symptoms.",
"     </li>",
"     <li>",
"      A trial compared 13 individuals treated with a benzodiazepine within one week of trauma exposure to 13 individuals with comparable trauma exposure who did not receive a benzodiazepine; participants in the two groups were pair matched for gender and symptom severity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/9\">",
"       9",
"      </a>",
"      ]. Ten patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      (mean dose 2.7",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      and three were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      (mean dose 2.5",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Participants in the two groups did not experience mean differences in PTSD severity ratings at one or six months. Nine participants in the benzodiazepine group compared to three controls met PTSD diagnostic criteria at six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1238727\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other medications have been studied in varied populations (including individuals experiencing a traumatic event, acutely traumatized, or diagnosed with ASD) with the objective of preventing the subsequent development of PTSD. These trials, limited by small sample sizes and yielding inconclusive findings, are inadequate to recommend the use of these medications for treatment of ASD symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2503272\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials found mixed results for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    in the treatment of children with ASD following severe burns. Negative results were also seen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    in one of the trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 25 children, age 2 to 19, who met ASD criteria following severe burns, compared treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/10\">",
"       10",
"      </a>",
"      ]. After daily treatment for seven days, patients were more likely to respond in the imipramine group compared to chloral hydrate (83 versus 38 percent).",
"     </li>",
"     <li>",
"      A trial of 60 children, age 4 to 18, with ASD symptoms following severe burns, compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/11\">",
"       11",
"      </a>",
"      ]. Following daily treatment for one week, a statistically significant difference in response was not seen among the three groups (60 and 72 versus 55 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2503279\">",
"    <span class=\"h3\">",
"     Propranolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    has been tested in the immediate aftermath of trauma exposure, with the hypothesis that reducing noradrenergic activation would result in reduced conditioning of the trauma memories and prevent the development of PTSD. Although positive results were initially seen in an uncontrolled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/12\">",
"     12",
"    </a>",
"    ] and in subsequent testing of fear conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/13\">",
"     13",
"    </a>",
"    ], the only randomized trial examining the development of PTSD symptoms was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/14\">",
"     14",
"    </a>",
"    ]. Negative results were also seen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    in that trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      41 patients with ASD symptoms following a traumatic event were randomly assigned a 10-day course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/13\">",
"       13",
"      </a>",
"      ]. The results reported a trend toward limiting subsequent fear conditioning in the propranolol group.",
"     </li>",
"     <li>",
"      48 patients who experienced an acute physical injury and were admitted to a surgical trauma center were randomly assigned to receive 14 days of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/14\">",
"       14",
"      </a>",
"      ]. Neither medication showed a benefit compared to placebo in PTSD or depressive symptoms at one, four, or eight months postinjury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2503286\">",
"    <span class=\"h3\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several uncontrolled studies have noted that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (which reduces norepinephrine), used for pain control in the initial 48 hours after trauma exposure, is linked to reduced subsequent PTSD symptoms, although the relationship between morphine and the development of PTSD has not been tested in randomized trials. They may point to the importance of pain management in preventing PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 696 US military personnel who experienced physical trauma compared the rate of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      use during early trauma care between those who subsequently developed PTSD and those who did not. Subjects with PTSD were less likely to have received morphine (OR 0.48, 95% CI 0.34 to 0.68) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 155 consecutive hospital admissions of patients after traumatic injury showed that those who developed PTSD had received lower doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      than those who had not developed PTSD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A dose-related association between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      use and subsequent development of PTSD was observed in an earlier analysis of 24 children who received inpatient medical care for treatment of acute burns [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24197/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21033609\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with ASD, we suggest first-line treatment with trauma-focused cognitive-behavioral therapy that includes exposure over supportive therapy or cognitive restructuring alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21033148\">",
"       'Cognitive-behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although early intervention is indicated in most patients with ASD, some patients may benefit from a delay in starting exposure therapy (eg, patients who are suicidal, acutely grieving, or have experienced extreme avoidance or dissociation in response to the trauma) so that urgent problems can be addressed through appropriate strategies, such as suicide management. (See",
"      <a class=\"local\" href=\"#H21033155\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT is typically provided in an individual format in five to six weekly, 60 to 90 minute sessions. (See",
"      <a class=\"local\" href=\"#H21033163\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest short-term benzodiazepine treatment of patients with ASD and intense anxiety or agitation, or sleep disturbance, in the immediate period following the traumatic event (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      0.5 to 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      can be used in divided doses. Prolonged treatment with a benzodiazepine beyond two weeks may be detrimental to adaptation, leading to higher rates of PTSD. (See",
"      <a class=\"local\" href=\"#H21033178\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/1\">",
"      Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. J Clin Psychiatry 2011; 72:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/2\">",
"      Bryant RA, Harvey AG, Dang ST, et al. Treatment of acute stress disorder: a comparison of cognitive-behavioral therapy and supportive counseling. J Consult Clin Psychol 1998; 66:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/3\">",
"      Bryant RA, Sackville T, Dang ST, et al. Treating acute stress disorder: an evaluation of cognitive behavior therapy and supportive counseling techniques. Am J Psychiatry 1999; 156:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/4\">",
"      Bryant RA, Moulds M, Guthrie R, Nixon RD. Treating acute stress disorder following mild traumatic brain injury. Am J Psychiatry 2003; 160:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/5\">",
"      Bryant RA, Moulds ML, Nixon RD, et al. Hypnotherapy and cognitive behaviour therapy of acute stress disorder: a 3-year follow-up. Behav Res Ther 2006; 44:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/6\">",
"      Korn&oslash;r H, Winje D, Ekeberg &Oslash;, et al. Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: a systematic review and meta-analysis. BMC Psychiatry 2008; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/7\">",
"      Bryant RA, Mastrodomenico J, Felmingham KL, et al. Treatment of acute stress disorder: a randomized controlled trial. Arch Gen Psychiatry 2008; 65:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/8\">",
"      Mellman TA, Byers PM, Augenstein JS. Pilot evaluation of hypnotic medication during acute traumatic stress response. J Trauma Stress 1998; 11:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/9\">",
"      Gelpin E, Bonne O, Peri T, et al. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996; 57:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/10\">",
"      Robert R, Blakeney PE, Villarreal C, et al. Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 1999; 38:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/11\">",
"      Robert R, Tcheung WJ, Rosenberg L, et al. Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study. Burns 2008; 34:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/12\">",
"      Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003; 54:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/13\">",
"      Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/14\">",
"      Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007; 20:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/15\">",
"      Norman SB, Stein MB, Dimsdale JE, Hoyt DB. Pain in the aftermath of trauma is a risk factor for post-traumatic stress disorder. Psychol Med 2008; 38:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/16\">",
"      Holbrook TL, Galarneau MR, Dye JL, et al. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med 2010; 362:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/17\">",
"      Bryant RA, Creamer M, O'Donnell M, et al. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009; 65:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24197/abstract/18\">",
"      Saxe G, Stoddard F, Courtney D, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry 2001; 40:915.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16867 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-DB1EE8AE99-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24197=[""].join("\n");
var outline_f23_40_24197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21033609\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21031615\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21033141\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21033148\">",
"      COGNITIVE-BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21033155\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21033163\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21033170\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21033178\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21033185\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1238727\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2503272\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2503279\">",
"      - Propranolol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2503286\">",
"      - Morphine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21033609\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=related_link\">",
"      Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_40_24198="Endosc resect and RFA HALO";
var content_f23_40_24198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Endoscopic and histological images of long-segment Barrett's esophagus with early cancer treated with a combination of endoscopic resection and radiofrequency ablation using the HALO system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (A)",
"    </strong>",
"    Antegrade view of Barrett's esophagus.",
"    <br>",
"     <strong>",
"      (B)",
"     </strong>",
"     A lesion suspicious for early cancer is noted from the 2 to 4 o'clock positions.",
"     <br>",
"      <strong>",
"       (C)",
"      </strong>",
"      View of the esophagus after endoscopic resection of the lesion in two pieces.",
"      <br>",
"       <strong>",
"        (D)",
"       </strong>",
"       Histopathological evaluation of the specimens showed a radically resected adenocarcinoma infiltrating the muscularis mucosae (T1m3).",
"       <br>",
"        <strong>",
"         (E)",
"        </strong>",
"        Same area six weeks after the endoscopic resection showing that the wound has healed completely with scarring.",
"        <br>",
"         <strong>",
"          (F)",
"         </strong>",
"         Esophagus after primary circumferential ablation using the HALO360 system (two applications at 12 J/cm2).",
"         <br>",
"          <strong>",
"           (G)",
"          </strong>",
"          Residual Barrett's mucosa six weeks after prior circumferential ablation.",
"          <br>",
"           <strong>",
"            (H)",
"           </strong>",
"           After additional focal ablation of the residual islands of Barrett's mucosa, complete ablation of the Barrett's segment was achieved.",
"           <div class=\"footnotes\">",
"           </div>",
"           <div class=\"reference\">",
"            Reproduced with permission of www.endosurgery.eu. Copyright &copy; 2010 Esophageal Research Foundation Amsterdam.",
"           </div>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24198=[""].join("\n");
var outline_f23_40_24198=null;
var title_f23_40_24199="Late gadolinium enhancement in myocardial infarction";
var content_f23_40_24199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Late gadolinium enhancement in myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short-axis (upper panel) and long-axis (lower panel) late gadolinium enhancement (LGE)&nbsp;cardiovascular&nbsp;magnetic resonance (CMR)&nbsp;images&nbsp;in three patients with large myocardial infarctions (MIs). Hyperenhanced regions (arrows) were large and predominantly transmural. In comparison, small infarcts (not shown) were not transmural.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Wu E, Judd RM, Vargas JD, et al. Lancet 2001; 357:21. Copyright &copy; 2001. The Lancet Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24199=[""].join("\n");
var outline_f23_40_24199=null;
var title_f23_40_24200="Screening for lower extremity peripheral artery disease";
var content_f23_40_24200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for lower extremity peripheral artery disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24200/contributors\">",
"     Rodney A Hayward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24200/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24200/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/40/24200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2945130\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral artery disease (PAD) of the lower extremities is a common cause of impaired ambulation and is a leading cause of lower extremity wounds and amputations. It is also associated with atherosclerosis elsewhere in the body. Thus, individuals with PAD are at significantly increased risk of cardiovascular and cerebrovascular events and mortality.",
"   </p>",
"   <p>",
"    There is substantial evidence that the majority of cases of PAD go undetected in routine clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As a result, there is considerable interest in detection of PAD through routine screening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, a systematic review of guidelines for peripheral artery disease screening found divergent recommendations among the eight screening guidelines identified from major organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/7\">",
"     7",
"    </a>",
"    ]. In the absence of a randomized trial evaluating outcomes of screening in asymptomatic individuals, critical questions regarding the objectives of screening, appropriateness of screening, and optimal approach to screening need to be addressed.",
"   </p>",
"   <p>",
"    This topic will review the rationale and recommendations for screening for PAD with a focus on the use of the ankle-brachial index (ABI) as a screening test. Clinical features of lower extremity PAD and noninvasive diagnostic tests for PAD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945137\">",
"    <span class=\"h1\">",
"     PREVALENCE OF PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of adults older than 55 years have PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/8\">",
"     8",
"    </a>",
"    ], although estimates of the prevalence of PAD vary widely. A large study in the United States that was conducted in 1999 to 2004 estimated that about 7.1 million community-dwelling Americans were diagnosed with PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence of PAD increases substantially with age.",
"   </p>",
"   <p>",
"    It is well documented that undiagnosed PAD is common. In a study of almost 7000 primary care patients who were 70 years or older or 50 to 69 years with risk factors for atherosclerosis (history of cigarette use or diabetes), PAD was identified in 29 percent either through ankle-brachial index (ABI) screening or prior documentation; over half of these cases were previously undiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of asymptomatic PAD in generally healthy populations, as opposed to clinic populations, is significantly lower. In a study sample of 1017 adults aged 60 to 69 years (average age 66 years) that excluded individuals with major chronic disease but did include smokers and patients with diabetes, the prevalence of PAD by ABI screening (ABI&lt;0.90) was 2 percent, but the prevalence was 6.6 percent in current smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/10\">",
"     10",
"    </a>",
"    ]. PAD was not significantly more common in subjects with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053330377\">",
"    <span class=\"h2\">",
"     Risk factors for PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to age, major risk factors for PAD are similar to those for other cardiovascular diseases (CVD): smoking, hyperlipidemia, hypertension, diabetes mellitus, and the diagnosis of atherosclerosis in other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/1,2,11,12\">",
"     1,2,11,12",
"    </a>",
"    ]. Smoking is a particularly strong risk factor for PAD, and is two to three times more strongly associated with PAD than with coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the Trans-Atlantic Inter-Society Consensus (TASC), a consortium of professional organizations, define increased risk for PAD as the presence of one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;50 years with diabetes and one additional risk factor (smoking, dyslipidemia, hypertension, or homocysteinemia)",
"     </li>",
"     <li>",
"      Age 50 to 69 years with history of smoking or diabetes",
"     </li>",
"     <li>",
"      Age &ge;70 years",
"     </li>",
"     <li>",
"      Abnormal lower extremity pulses",
"     </li>",
"     <li>",
"      Leg symptoms with exertion or ischemic rest pain",
"     </li>",
"     <li>",
"      Known coronary, carotid, or renal atherosclerosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 2011 update of their 2005 guideline, the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association (in collaboration with other participants of the TASC consortium) recategorized risk as age &ge;65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053330043\">",
"    <span class=\"h1\">",
"     DIAGNOSING PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAD is frequently unrecognized by clinicians, and can be overlooked even when the patient has symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ]. Primary care physicians are often unaware that patients have PAD, even when the patient is aware of his or her diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Classic claudication symptoms are found in only a minority of patients with PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/15\">",
"     15",
"    </a>",
"    ]. Classic intermittent claudication is defined as exertional calf pain that causes a person to stop walking, and resolves within 10 minutes of rest. In a report of 460 consecutive PAD patients, only 32 percent had classic intermittent claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/15\">",
"     15",
"    </a>",
"    ]. Twenty percent had no exertional leg pain and almost half (48 percent) had atypical symptoms, such as rest and exertional leg pain, leg pain other than in the calf, pain that did not cause the patient to stop walking, or pain that lasted more than 10 minutes after cessation of exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic patients with PAD may simply be more sedentary than those with intermittent claudication symptoms. Support for this hypothesis was provided by a study of patients with PAD in which those who never experienced symptoms had poorer functional performance and poorer quality of life than patients with PAD and exertional leg pain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053330050\">",
"    <span class=\"h2\">",
"     Ankle-brachial index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings from clinical examination (eg, skin temperature, peripheral pulses, or bruits) have poor sensitivity in the detection of PAD in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/17\">",
"     17",
"    </a>",
"    ]. The ankle-brachial index (ABI) is a simple, accurate, and relatively inexpensive test that assesses the ratio of systolic pressures in the lower versus upper extremities using Doppler ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/18\">",
"     18",
"    </a>",
"    ]. Techniques for performing this assessment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABI predicts angiography results more accurately than is possible using history and physical examination alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"     3",
"    </a>",
"    ]. In patients undergoing diagnostic testing, ABI has excellent overall accuracy compared to angiography (area under ROC curve = 0.95) in detecting significant PAD (stenoses &ge;50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/19\">",
"     19",
"    </a>",
"    ]. For patients in whom there is clinical suspicion of PAD, an ABI cutoff of &lt;0.9 has been reported to have a sensitivity ranging from 79 to 95 percent with specificity consistently &gt;95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"     3",
"    </a>",
"    ]. Little information is available on the sensitivity and specificity of ABI when used in asymptomatic patients without other known vascular disease (ie, a screening population). A modified approach to calculating ABI (using the lowest ankle pressure for each leg divided by the highest brachial pressure) has been demonstrated to have a higher positive test rate in a screening population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/10\">",
"     10",
"    </a>",
"    ], but this approach requires validation and a more complete assessment of its impact on specificity and sensitivity.",
"   </p>",
"   <p>",
"    The ABI is considered sufficiently accurate so that verifying the diagnosis using arterial angiography is generally not recommended. Lower extremity angiography is appropriately reserved for those with advanced disease in whom surgical intervention is being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053330493\">",
"    <span class=\"h1\">",
"     RATIONALE FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for screening to detect patients with asymptomatic PAD is based upon two possible objectives [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To identify early PAD and intervene to prevent progression and complications directly related to PAD.",
"     </li>",
"     <li>",
"      To identify patients at high risk for coronary heart disease (high-CHD risk) or other cardiovascular disease (CVD) to aggressively treat risk factors and prevent events related to CVD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To achieve the first objective, the risk of progression from asymptomatic PAD to critical leg ischemia would need to be high enough to warrant intervention in individuals identified by screening, the interventions would need to be safe and have proven efficacy for the prevention of PAD progression, and the interventions would need to be those that would not otherwise be implemented in the absence of screening.",
"   </p>",
"   <p>",
"    Similarly, to achieve the second objective, the risk of CHD or stroke in patients who otherwise had not been identified as high risk would need to be significant, the interventions would need to be proven safe and effective for prevention of CHD or other CVD events in patients identified with asymptomatic PAD, and the interventions would need to be those otherwise not indicated if screening for PAD were not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053330256\">",
"    <span class=\"h2\">",
"     PAD as a risk factor for other cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations to use ABI testing for screening selected populations are mainly based upon identifying patients at high risk for CVD, with the expectation that this would lead to more aggressive risk factor modification than would occur in the absence of screening. PAD screening is one of a host of proposed tests for identification of high CVD-risk patients, including estimation of CVD risk using multivariable prediction tools, such as the Framingham CVD risk score. Other studies include C-reactive protein, apoprotein B, LDL subparticles, homocysteine, and CT cardiac screening. The marginal utility that these tests add to widely used risk scores is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is well established that PAD is a risk factor for other CVD and that the risk is greater with more advanced PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/20-26\">",
"     20-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large international registry of patients found that 5.4 percent of patients with established PAD had a major cardiovascular event (CV death, MI, or stroke) at one year, and 21 percent experienced these endpoints or hospitalization for an atherosclerotic event [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/23\">",
"       23",
"      </a>",
"      ]. These rates were comparable to event rates for patients with coronary artery or cerebrovascular disease.",
"     </li>",
"     <li>",
"      Eleven-year follow-up in the Cardiovascular Health Study found, after controlling for other risk factors, an almost two-fold increased risk for mortality in participants with ABI 0.71 to 0.8 (HR 1.80) and 0.81 to 0.9 (HR 1.73) compared to those with ABI 1.1 to 1.2 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of nine studies evaluating ABI and subsequent cardiovascular outcomes for patients with ABI 0.8 to 0.9 compared to those with normal ABI, likelihood ratios for CHD, stroke, and cardiovascular death were 2.5, 2.5, and 5.6, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/22\">",
"       22",
"      </a>",
"      ]. More than half of the patients with low ABI were asymptomatic and identified through screening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Half of those with PAD have known CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/27\">",
"     27",
"    </a>",
"    ] and the majority of the rest have other major risk factors for PAD that would qualify them for aggressive risk factor modification [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ]. However, ABI remains an independent predictor of cardiovascular risk after adjusting for conventional risk factors, and has some incremental value in assessing risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. A meta-analysis of sixteen cohort studies comparing cardiovascular risk predicted by the Framingham risk score compared to risk predicted by the ABI found that inclusion of the ABI in the cardiovascular risk stratification would lead to reclassification of risk and change in treatment recommendations, such as lipid-lowering therapy as recommended by ATP III guidelines, for about one-fifth of men and one-third of women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053330166\">",
"    <span class=\"h1\">",
"     INTERVENTIONS FOR ASYMPTOMATIC PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;While risk factor modification is essential for all patients with PAD to reduce their risk of CVD (control of tobacco use, hyperlipidemia, hypertension, hyperglycemia, and increasing exercise), the effect of such interventions on progression of PAD per se is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945160\">",
"    <span class=\"h2\">",
"     Intervening for PAD outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 5 to 10 percent of individuals with asymptomatic PAD develop symptoms of PAD over five years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/33\">",
"     33",
"    </a>",
"    ]. Critical leg ischemia occurs infrequently (1 to 2 percent of patients with PAD), but is more likely to affect patients with concomitant diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence suggests that smoking cessation and gradually progressive walking programs can slow disease progression and improve PAD symptoms and functional impairment for patients with symptomatic PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/8,34\">",
"     8,34",
"    </a>",
"    ]. Supervised exercise was more effective than stent revascularization for improving treadmill walking performance in a randomized trial of individuals with symptomatic PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/35\">",
"     35",
"    </a>",
"    ]. A clinical trial of 882 men with PAD detected by screening with a claudication questionnaire and ankle-brachial index found that, compared to \"usual care,\" a \"stop smoking and keep walking\" program resulted in about a 50 percent increase in the number of men who improved their maximum walking performance at 12-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/36\">",
"     36",
"    </a>",
"    ]. Whether exercise can prevent progression of PAD in truly asymptomatic patients is not clear from these data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is scant evidence whether treatment for other risk factors, such as elevated lipids and blood pressure, affects PAD onset and progression. Benefit of different lipid-lowering agents on total walking distance and pain-free walking distance was demonstrated in a meta-analysis of several small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/37\">",
"     37",
"    </a>",
"    ]. One cross-sectional study found that statin therapy was associated with better ambulatory function in patients with known PAD, independent of cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, interventions directed at preventing PAD progression are either universally recommended (increased physical activity and smoking cessation) or are more important for CVD morbidity and mortality reduction (treatment for elevated blood pressure and dyslipidemia). There is no evidence to suggest that early revascularization in selected patients with asymptomatic PAD prevents progression to symptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053329675\">",
"    <span class=\"h2\">",
"     Intervening for CVD outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious cardiovascular complications are more common than serious complications of PAD; therefore,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, blood pressure control and statin therapy should be primarily based upon cardiovascular risk assessment. Some observational studies, with adjustment for known cardiovascular risks, suggest that use of statins, aspirin, and antihypertensive agents in patients with established PAD are independently associated with reduced long-term mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/39\">",
"     39",
"    </a>",
"    ]. However, since these treatments are generally recommended for all patients with an elevated CVD risk, the benefits of PAD screening in patients with known increased risk for CVD is unclear.",
"   </p>",
"   <p>",
"    Assessment for PAD has intuitive appeal for helping to guide treatment decisions for patients at intermediate risk of CVD after conventional risk factor appraisal. However, it is not known whether patients identified at increased risk because of low ABI would receive greater benefit from treatment, or that awareness of increased risk would make patients more likely to comply with recommended interventions. Furthermore, it is unclear whether a normal ABI should make clinicians and patients less likely to treat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162503561\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data supporting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for primary prevention of cardiovascular disease (coronary heart disease and stroke) are less conclusive than for secondary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although measuring ABI could identify a population at increased risk for CVD compared to the general population, the effectiveness of primary prevention has also not been proven in this higher risk group.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial in 3350 asymptomatic screened individuals aged 50 to 75 years with an ABI &lt;0.95 found no difference in rates of coronary events, stroke, or revascularization for those randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      100 mg daily or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/40\">",
"       40",
"      </a>",
"      ]. Aspirin was associated with a statistically nonsignificant increased risk of major hemorrhage (HR 1.71; 95% CI 0.99-2.97).",
"     </li>",
"     <li>",
"      Even in patients with diagnosed PAD, a meta-analysis of randomized trials found a non-significant decrease in cardiovascular events, but no reduction in MI, cardiovascular or all-cause mortality, for patients who were randomly assigned to daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162503569\">",
"    <span class=\"h3\">",
"     Walking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence suggests that functional assessment of walking fitness can help identify those at higher CVD risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In one study, poor walking fitness was as strong an independent CVD risk factor as smoking and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/43\">",
"     43",
"    </a>",
"    ]. Whether walking fitness in part helps identify those with functionally important occult PAD is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162503883\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized trials found that lipid-lowering therapy, primarily statins, reduced cardiovascular mortality and morbidity in people with diagnosed PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/37\">",
"     37",
"    </a>",
"    ]. Eighteen trials (10,049 participants) with varying inclusion criteria were included in the meta-analysis; although pooled results from all trials did not find a statistically significant effect on mortality or cardiovascular events, a subgroup analysis that excluded one trial in which treatment (probucol) had a detrimental effect on lipid levels did identify significantly improved cardiovascular and mortality outcomes. The effectiveness of lipid-lowering in patients with asymptomatic PAD was not addressed",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945188\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 systematic review of guidelines on screening for peripheral artery disease (PAD) identified eight guidelines in English from national and international medical societies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/7\">",
"     7",
"    </a>",
"    ]. PAD screening for individuals at high risk for cardiovascular disease was advocated in five guidelines, while three found the evidence insufficient to recommend screening. The evidence used as the basis for the guidelines primarily derived from studies of patients with established PAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945197\">",
"    <span class=\"h2\">",
"     The TASC II report",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC) was first published in 2000, and updated in 2007 (TASC II) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/44\">",
"     44",
"    </a>",
"    ]. Representing a consensus of sixteen medical and surgical specialty societies from five continents, the guidelines recommend screening for PAD by ABI measurement in primary care for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects with exertional leg symptoms (not truly screening)",
"     </li>",
"     <li>",
"      Subjects age 50 to 69 with cardiovascular risk factors",
"     </li>",
"     <li>",
"      All patients 70 years of age or older",
"     </li>",
"     <li>",
"      Subjects with a 10-year risk of a cardiovascular event between 10 and 20 percent, as determined by SCORE or Framingham Heart Association guidelines",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945204\">",
"    <span class=\"h2\">",
"     American College of Cardiology/American Heart Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;2005 guidelines from the American College of Cardiology and American Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    state that individuals with asymptomatic lower extremity PAD should be identified by examination (comprehensive pulse palpation and inspection of the feet)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    measurement of the ABI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"     3",
"    </a>",
"    ]. A 2011 update of the 2005 guidelines advises &ldquo;consideration of diagnostic ABI&rdquo; for individuals at risk defined by any one of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lt;50 years with diabetes and an additional CVD risk factor",
"     </li>",
"     <li>",
"      &ge;50 years with a history of smoking or diabetes",
"     </li>",
"     <li>",
"      &ge;65 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945211\">",
"    <span class=\"h2\">",
"     American College of Physicians",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2007 publication states that there is no evidence to document that routine screening for PAD with ABI improves patient outcomes. Clinicians should consider looking for history and physical examination evidence of PAD in patients at high risk (&gt;65 years, smokers, African Americans, and patients with diabetes &gt;age 50) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945218\">",
"    <span class=\"h2\">",
"     US Preventive Services Task Force",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 US Preventive Services Task Force (USPSTF) guideline on screening for PAD recommends against routine screening and concludes that harms of routine screening for PAD (unnecessary work-ups for false-positive results) exceed benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/5\">",
"     5",
"    </a>",
"    ]. It should be noted that the USPSTF only looked at the potential outcome of decreased morbidity related to PAD (claudication, amputation, and impaired ambulation), and did not consider morbidity or mortality issues related to the risk of cardiovascular events in that analysis. In a subsequent set of recommendations regarding the use of nontraditional risk factors, including ABI, for the evaluation of coronary heart disease (CHD), the USPSTF found that the evidence was insufficient to determine the effect of screening with ABI on the occurrence of CHD events or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24200/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1418824119\">",
"    <span class=\"h2\">",
"     Synthesis of evidence and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data that have emerged since these groups last issued guidelines lend support to the link between low ABI and increased risk for MI, stroke, and overall mortality. Additionally, a low ABI adds incremental value in stratifying risk for CVD beyond risk calculations based on factors incorporated in the Framingham risk score. However, it remains to be determined whether interventions for asymptomatic patients identified at increased risk by ABI score will be effective in reducing morbidity and mortality, and randomized trials are awaited. Pending results of such trials, we suggest not screening for PAD or CVD risk with ABI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"       \"Patient information: Atherosclerosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2945225\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity peripheral artery disease (PAD) is caused by occlusion of vessels beyond the bifurcation of the aorta and is due to atherosclerosis in the vast majority of cases. (See",
"      <a class=\"local\" href=\"#H2945130\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for PAD are: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age &lt;50 years with diabetes and one additional risk factor (smoking, dyslipidemia, hypertension, or homocysteinemia)",
"     </li>",
"     <li>",
"      Age 50 to 69 years with history of smoking or diabetes",
"     </li>",
"     <li>",
"      Age &gt;70 years",
"     </li>",
"     <li>",
"      Known coronary, carotid, or renal atherosclerosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PAD is also suggested by the presence of abnormal lower extremity pulses, or symptoms of claudication or ischemic rest pain. (See",
"    <a class=\"local\" href=\"#H1053330377\">",
"     'Risk factors for PAD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low ankle-brachial index (&lt;0.9) has 90 percent sensitivity and 95 specificity for PAD. Claudication is uncommon in patients with PAD. In the absence of screening, PAD is not diagnosed in more than one-half of patients who meet ABI criteria for PAD. (See",
"      <a class=\"local\" href=\"#H1053330043\">",
"       'Diagnosing PAD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale for screening for PAD involves both the potential to intervene to prevent progression of PAD and to decrease risk for other cardiovascular disease. The association between low ABI and risk for major cardiovascular events is well established and a low ABI is an independent risk factor. (See",
"      <a class=\"local\" href=\"#H1053330493\">",
"       'Rationale for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progression from asymptomatic PAD to limb threatening disease is uncommon and interventions directed at preventing PAD progression are universally recommended (increased physical activity and smoking cessation). (See",
"      <a class=\"local\" href=\"#H2945160\">",
"       'Intervening for PAD outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions for patients with low ABI to decrease the risk of other CVD include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , lipid lowering therapy, and walking. A randomized trial of aspirin in patients with asymptomatic PAD did not reduce rates of coronary events, stroke, or revascularization. It is not known if statin therapy will benefit individuals who have a positive ABI screening but whose CVD risk is low by conventional risk factors (such as Framingham CVD Risk Score). There is inadequate evidence to determine if ABI adds to conventional CVD risk assessment methods and how ABI compares to other interventions to supplement conventional CVD risk assessment, such as measuring the coronary calcium score. (See",
"      <a class=\"local\" href=\"#H1053329675\">",
"       'Intervening for CVD outcomes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"       \"Screening for coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      International consensus guidelines from 2007 (TASC II) and",
"      <span class=\"nowrap\">",
"       2006/2007",
"      </span>",
"      guidelines from several US organizations suggest ABI screening for higher-risk individuals. The USPSTF recommended against screening, but considered only the impact of screening on PAD morbidity and not morbidity or mortality related to the risk of cardiovascular events. (See",
"      <a class=\"local\" href=\"#H2945188\">",
"       'Recommendations of others'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using ABI measurements for screening to detect PAD or CVD risk (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1418824119\">",
"       'Synthesis of evidence and recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/1\">",
"      Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/2\">",
"      Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/3\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/4\">",
"      Beckman JA, Jaff MR, Creager MA. The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit? Circulation 2006; 114:861.",
"     </a>",
"    </li>",
"    <li>",
"     United States Preventive Services Task Force. Screening for peripheral arterial disease: recommendation statement 2005. Available at: www.preventiveservices.ahrq.gov (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     United States Preventive Services Task Force. Recommendation Statement: Screening for Peripheral Arterial Disease. Agency for Healthcare Research and Quality, Washington, DC 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/7\">",
"      Ferket BS, Spronk S, Colkesen EB, Hunink MG. Systematic review of guidelines on peripheral artery disease screening. Am J Med 2012; 125:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/8\">",
"      Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/9\">",
"      Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/10\">",
"      Taylor-Piliae RE, Fair JM, Varady AN, et al. Ankle brachial index screening in asymptomatic older adults. Am Heart J 2011; 161:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/11\">",
"      Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/12\">",
"      Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA 2012; 308:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/13\">",
"      Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999; 20:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/14\">",
"      Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/15\">",
"      McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/16\">",
"      McDermott MM, Guralnik JM, Ferrucci L, et al. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 2008; 117:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/17\">",
"      Khan NA, Rahim SA, Anand SS, et al. Does the clinical examination predict lower extremity peripheral arterial disease? JAMA 2006; 295:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/18\">",
"      Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/19\">",
"      Lijmer JG, Hunink MG, van den Dungen JJ, et al. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996; 22:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/20\">",
"      Vogt MT, McKenna M, Wolfson SK, Kuller LH. The relationship between ankle brachial index, other atherosclerotic disease, diabetes, smoking and mortality in older men and women. Atherosclerosis 1993; 101:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/21\">",
"      Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/22\">",
"      Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005; 25:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/23\">",
"      Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/24\">",
"      O'Hare AM, Katz R, Shlipak MG, et al. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006; 113:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/25\">",
"      Criqui MH, Ninomiya JK, Wingard DL, et al. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008; 52:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/26\">",
"      Feringa HH, Karagiannis SE, Schouten O, et al. Prognostic significance of declining ankle-brachial index values in patients with suspected or known peripheral arterial disease. Eur J Vasc Endovasc Surg 2007; 34:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/27\">",
"      Murabito JM, Evans JC, Larson MG, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 2003; 163:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/28\">",
"      Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/29\">",
"      Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/30\">",
"      Ramos R, Quesada M, Solanas P, et al. Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg 2009; 38:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/31\">",
"      van Kuijk JP, Flu WJ, Bax JJ, Poldermans D. Prevalence of (a)symptomatic peripheral arterial disease; the additional value of ankle-brachial index on cardiovascular risk stratification. Eur J Vasc Endovasc Surg 2009; 38:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/32\">",
"      Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/33\">",
"      Hooi JD, Stoffers HE, Knottnerus JA, van Ree JW. The prognosis of non-critical limb ischaemia: a systematic review of population-based evidence. Br J Gen Pract 1999; 49:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/34\">",
"      McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/35\">",
"      Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012; 125:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/36\">",
"      Fowler B, Jamrozik K, Norman P, et al. Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial. Aust J Physiother 2002; 48:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/37\">",
"      Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007; :CD000123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/38\">",
"      McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/39\">",
"      Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/40\">",
"      Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/41\">",
"      Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/42\">",
"      Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/43\">",
"      Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 1999; 282:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/44\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/45\">",
"      Wilson JF, Laine C, Goldmann D. In the clinic. Peripheral arterial disease. Ann Intern Med 2007; 146:ITC3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24200/abstract/46\">",
"      U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15238 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24200=[""].join("\n");
var outline_f23_40_24200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2945225\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2945130\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2945137\">",
"      PREVALENCE OF PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053330377\">",
"      Risk factors for PAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1053330043\">",
"      DIAGNOSING PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053330050\">",
"      Ankle-brachial index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1053330493\">",
"      RATIONALE FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053330256\">",
"      PAD as a risk factor for other cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1053330166\">",
"      INTERVENTIONS FOR ASYMPTOMATIC PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2945160\">",
"      Intervening for PAD outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053329675\">",
"      Intervening for CVD outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1162503561\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1162503569\">",
"      - Walking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1162503883\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2945188\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2945197\">",
"      The TASC II report",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2945204\">",
"      American College of Cardiology/American Heart Association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2945211\">",
"      American College of Physicians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2945218\">",
"      US Preventive Services Task Force",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1418824119\">",
"      Synthesis of evidence and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2945225\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=related_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_40_24201="Preoperative management of patients with cancer";
var content_f23_40_24201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preoperative management of patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Ellen F Manzullo, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Sunil K Sahai, MD, FAAP, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Harrison G Weed, MS, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24201/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/40/24201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative management of the patient with cancer can be complex. While patients with cancer are similar in many ways to those without cancer, the direct and indirect (systemic) effects of the cancer and the side effects of cancer therapy can influence perioperative evaluation and management. Here we will provide an overview of issues that are relevant to patients with active or past cancer. General preoperative evaluation and estimation of cardiac risk from surgery are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preoperative medical evaluation of cancer patients should include an assessment of nutritional status, functional status, and symptom control (particularly regarding pain) in addition to an assessment of general medical issues. The natural history of the cancer and effects of any prior chemotherapy or radiation therapy should also be considered. The short- and long-term outcomes of cancer surgery in older patients can be equivalent to those in younger patients. Treatment considerations should be based on functional status, not on chronological age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing and purpose of the cancer surgery can affect perioperative evaluation. While rarely emergent, cancer surgery is usually not elective, and therefore the amount of time available to medically optimize a patient may be limited.",
"   </p>",
"   <p>",
"    In addition to managing coexisting medical conditions, the internist may also play an important role in coordinating the many complex levels of care provided by surgeons, medical oncologists, radiation oncologists, and others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer may become significantly malnourished for a variety of reasons. Eating and drinking can be impaired by pain, nausea, stomatitis, or tumors involving the oropharynx or gastrointestinal tract. Furthermore, metabolic aberrations may induce anorexia and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indiscriminate use of enteral or parenteral nutrition is not indicated in well-nourished patients or those with mild malnutrition. Although many studies have failed to demonstrate a survival benefit from preoperative nutritional support in patients undergoing cancer surgery, some have found fewer operative complications and a shorter length of hospital stay in severely malnourished patients receiving nutritional support prior to major surgery for cancers of the digestive tract and the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H5#H5\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'The perioperative setting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, preoperative nutritional support for cancer patients is reasonable in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven to ten days of preoperative parenteral nutritional support for severely malnourished cancer patients prior to major visceral surgery",
"     </li>",
"     <li>",
"      One to two weeks of enteral nutritional support via a gastrostomy or jejunostomy feeding tube for severely malnourished patients prior to major head and neck cancer surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer often require medication for pain control. Those who have been receiving opioid analgesics can be expected to have some degree of tolerance and may require dose escalation in the postoperative period to attain adequate pain control. Many patients will be receiving long-acting forms of opioids and may require conversion to short-acting forms of analgesia in the perioperative period. Conversion tables are available (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in other surgical patients, medications used for pain control in patients with cancer can have important side effects. NSAIDs can cause bleeding, gastritis, and impaired renal function, and opioids can cause nausea, constipation, sedation, and delirium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NSAIDs may be contraindicated in patients with thrombocytopenia from cancer or its treatment, and in patients with impaired renal function. Selective COX-2 inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) do not increase nongastrointestinal bleeding risk, but as with other NSAIDs, they do increase the risk of renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may have concerns about postoperative pain control. These should be addressed as part of the preoperative evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CARDIAC STATUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiac assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must integrate information from the history, physical examination, and electrocardiogram in order to develop an initial estimate of perioperative cardiac risk. The 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on perioperative cardiovascular evaluation for noncardiac surgery concluded that three elements must be assessed to determine the risk of cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient specific clinical variables (",
"      <a class=\"graphic graphic_table graphicRef62292 \" href=\"UTD.htm?26/56/27532\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Exercise capacity",
"     </li>",
"     <li>",
"      Surgery-specific risk (",
"      <a class=\"graphic graphic_table graphicRef57828 \" href=\"UTD.htm?7/2/7212\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections address specific issues that arise in patients with cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pericardial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer are at risk for malignant and nonmalignant pericardial disease. Metastases to the pericardium can cause effusions, tamponade, and constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy to the mediastinum can also cause constrictive pericarditis, or effusions with or without tamponade. Pericarditis can present months to years after radiation treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography should be performed if physical examination reveals possible evidence of tamponade or constriction (eg, hypotension, jugular venous distension, narrowed pulse pressure, distant heart sounds, or excessive respiratory variation in blood pressure) or if electrocardiography or imaging suggests a significant pericardial effusion.",
"   </p>",
"   <p>",
"    Tamponade and constrictive pericarditis must be treated prior to surgery whenever possible. Patients with asymptomatic malignant pericardial effusions should be carefully monitored for the development of tamponade in the perioperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coronary and cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy to fields that include the heart can lead to premature coronary heart disease (CHD). Radiation to the heart may also be associated with conduction abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore, younger patients who might not otherwise be expected to be at risk for CHD, but who have a history of thoracic radiation therapy for cancer should be assessed for symptomatic CHD as part of the preoperative history, and should have a preoperative electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy has also been associated with valvular heart disease, particularly of the mitral and aortic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]; therefore, careful cardiac auscultation is an important part of the preoperative examination. However, antibiotic prophylaxis is not necessarily needed in these cases. The 2007 AHA guideline for the prevention of infective endocarditis narrowed the indications for bacterial endocarditis prophylaxis, compared with prior versions, in recognition of the absence of strong supportive evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/8\">",
"     8",
"    </a>",
"    ]. Antimicrobial prophylaxis is not indicated unless the patient has a history of endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac toxicity from chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain chemotherapeutic agents, particularly the anthracyclines, cause significant cardiotoxicity. Dose-dependent cardiomyopathy and heart failure may be seen in patients who have received cumulative doses of over 550",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or 600",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/9\">",
"     9",
"    </a>",
"    ]. Preexisting heart disease, radiation therapy, and exposure to other chemotherapeutic agents (eg, taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ) can lower the cumulative dose threshold at which cardiomyopathy develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrocardiographic abnormalities such as sinus tachycardia, premature atrial or ventricular contractions, nonspecific ST and T wave changes, and low-voltage QRS complexes may be early signs of cardiotoxicity, but are insensitive indicators of myocardial dysfunction. Formal assessment of left ventricular function before surgery should be considered in patients who are at risk for cardiomyopathy since they are at increased risk for heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/10\">",
"     10",
"    </a>",
"    ]. Perioperative management is similar to that of other patients with heart failure who require surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=see_link\">",
"     \"Perioperative heart failure in noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY MASS EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tumors in or adjacent to the central airway are at risk for airway obstruction. Stridor, or other signs or symptoms of upper airway obstruction, should be assessed preoperatively by laryngoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anterior and middle mediastinal masses can compress the lower airways, heart, and major vessels. This can lead to life-threatening airway obstruction or to cardiopulmonary arrest during any phase of general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, the preoperative evaluation of a patient with an anterior or middle mediastinal mass should include a detailed review for respiratory symptoms including stridor, dyspnea, wheezing, and orthopnea, and examination for evidence of neck or chest vein engorgement or swelling restricted to the face and neck. Imaging of the chest with CT or MRI and echocardiography should be performed to look for central airway, cardiac, or vascular compression. Flow volume loops should also be obtained to look for central airway compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of mediastinal masses\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with any evidence of central airway, cardiac, or major vessel compression may require special anesthetic care and precautions, including but not limited to the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fiberoptic intubation while awake",
"     </li>",
"     <li>",
"      Spontaneous ventilation throughout surgery",
"     </li>",
"     <li>",
"      Quick repositioning of the patient to the lateral, prone, or sitting position as needed",
"     </li>",
"     <li>",
"      Rigid bronchoscopy in the event of a collapsed airway",
"     </li>",
"     <li>",
"      Femoral-femoral cardiopulmonary bypass in the event of cardiovascular collapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If surgery is being performed for the purpose of pathologic diagnosis of a mediastinal tumor that is causing compression, serious consideration should be given to alternate diagnostic strategies that would not require general anesthesia, such as lymph node biopsy or pleural or sputum cytology. However, in patients with superior vena cava syndrome, invasive procedures such as bronchoscopy and thoracoscopy can be carried out under general anesthesia with minimal risk of complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link&amp;anchor=H17#H17\">",
"     \"Malignancy-related superior vena cava syndrome\", section on 'Histologic diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PULMONARY ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment-related pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both chemotherapy and radiation can produce pulmonary toxicity that may be intensified when both are administered concomitantly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    may be associated with significant pulmonary toxicity in up to 10 percent of patients, and treatment with supplemental inhaled oxygen (as might occur during general anesthesia) may induce pulmonary toxicity several years after bleomycin treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other preoperative patients who may have pulmonary deficits, patients exposed to chest radiation therapy or chemotherapy should undergo a thorough history, physical examination, and a preoperative chest radiograph. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary function testing and measurement of oxygen saturation may be appropriate for selected patients with unexplained symptoms or abnormal examination findings. Patients at risk of postoperative pulmonary complications can benefit from special perioperative care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pleural effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a pleural effusion that is large enough to be symptomatic may benefit from therapeutic thoracentesis prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ENDOCRINE AND ELECTROLYTE STATUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many chemotherapeutic regimens include glucocorticoids, either as a therapeutic agent or as a component of premedication to prevent chemotherapy-induced nausea and vomiting or an infusion reaction. Glucocorticoids may unmask occult diabetes or exacerbate previously controlled blood sugar levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\"",
"    </a>",
"    .) Standard recommendations for perioperative management of diabetes are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are taking 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent for more the three weeks may or may not have suppression of the hypothalamic-pituitary-adrenal (HPA) axis and be at risk for insufficient adrenal response to the stress of surgery. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Adrenal insufficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative hyponatremia, particularly as a result of SIADH, can occur in cancer patients, and may be caused by the tumor or by treatments. Although it is preferable to correct hyponatremia before surgery, asymptomatic hyponatremia is not associated with increased perioperative risk, provided that a normal extracellular fluid volume is maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a common complication of cancer, occurring in up to 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/15\">",
"     15",
"    </a>",
"    ]. Therefore, a preoperative screening serum calcium determination is often appropriate. If hypercalcemia is identified, the patient's hydration should be optimized and calcium levels normalized prior to surgery, if feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency can occur in cancer patients as a result of adrenal suppression from chronic glucocorticoid treatment, or less commonly, from metastatic disease to both adrenal glands. The presence or absence of adrenal suppression, and therefore, the need for perioperative \"stress-dose\" glucocorticoid coverage, can usually be predicted from the dose and duration of the patient's glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HPA axis suppression should be assumed to be present in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose greater than 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three weeks or more, and in patients with a Cushingoid appearance.",
"     </li>",
"     <li>",
"      In general, patients who have taken any dose of glucocorticoids for less than three weeks or who have taken chronic alternate day therapy are unlikely to have a suppressed HPA axis and should continue on their usual dose of glucocorticoids perioperatively.",
"     </li>",
"     <li>",
"      Patients on intermediate doses of glucocorticoids should undergo testing, although many clinicians prefer empiric treatment with \"stress-dose\" glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adrenal insufficiency should be considered in postoperative patients with hypotension that is unresponsive to intravenous fluid boluses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy of the neck can cause hypothyroidism. In one study, 41 percent of patients with Hodgkin lymphoma who received 15 to 40 Gy to the cervical lymph nodes had hypothyroidism 20 years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/16\">",
"     16",
"    </a>",
"    ]. In another study, almost 60 percent of patients with Hodgkin lymphoma who had received mantle field irradiation had an elevated level of thyroid stimulating hormone (TSH) 10 to 18 years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/17\">",
"     17",
"    </a>",
"    ]. Because hypothyroidism causes poor surgical site healing, prior to surgery the serum TSH and free T4 concentrations should be measured in patients who have received more than 10 Gy total dose to the neck, and hypothyroidism should be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothyroidism may also complicate long-term treatment with the tyrosine kinase inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and (to a lesser extent)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651229244#H1651229244\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Thyroid dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Carcinoid crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid crisis is a life-threatening form of carcinoid syndrome that may be triggered by tumor manipulation (palpation at the bedside, biopsy, or during surgery) or by induction of anesthesia. Carcinoid crisis presumably arises because of the release of an overwhelming amount of biologically active compounds, such as catecholamines, that are produced by the tumor. Symptoms include flushing, diarrhea, tachycardia, arrhythmias, hypertension or hypotension, bronchospasm, and delirium.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    should be readily available during any surgical procedure. Preoperative administration of octreotide subcutaneously can reduce the incidence of carcinoid crisis and is routine in patients undergoing surgery for a carcinoid tumor except in the setting of bronchial carcinoids, which only rarely secrete bioactive amines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948942#H190948942\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pheochromocytoma surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas are rare catecholamine-secreting neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and the sympathetic ganglia (sometimes referred to as extra-adrenal catecholamine-secreting paragangliomas or extra-adrenal pheochromocytomas). Some form of preoperative pharmacologic preparation is indicated for all patients with catecholamine-secreting neoplasms. Preoperative medical therapy (typically starting with pharmacologic alpha-adrenergic followed by beta-adrenergic blockade) is aimed at controlling hypertension (including preventing a hypertensive crisis during surgery) and ensuring adequate intravascular volume prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of pheochromocytoma in adults\", section on 'Medical preparation for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC STATUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hypercoagulability",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypercoagulable state is common in patients with cancer, particularly those with advanced disease and primary brain tumors, and may be due to increased plasma levels of clotting factors, cytokines, or cancer procoagulant A, or to increased release of tissue plasminogen activator. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercoagulability (leading to arterial [myocardial infarction and stroke] as well as venous thrombosis) is also a potential side effect of cancer treatment with certain drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) and drug combinations (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In evaluating a patient with cancer before surgery, the physician faces the challenging task of estimating the risk for perioperative deep vein thrombosis and, in collaboration with the surgeon, determining the appropriate level of prophylactic treatment. Specific recommendations for prophylactic treatment are available from expert groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neutropenia and lymphopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are myelosuppressed as a result of chemotherapy or hematologic malignancy are at increased risk of infection. The risk is higher with longer durations of neutropenia and lymphopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever possible, non-emergent surgery should be postponed in neutropenic patients. Postoperative fever is common, and if it develops in the setting of neutropenia, aggressive diagnostic and therapeutic interventions are necessary. As discussed in more detail separately, neutropenic fever in any setting requires the prompt administration of broad spectrum antimicrobials. Even when neutropenia has resolved, patients receiving myelosuppressive chemotherapy remain relatively immunocompromised for a period of time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hematologic cancers such as chronic lymphocytic leukemia are predisposed to infection, particularly if they are treated with purine analogs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ). These issues should be considered in the perioperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia can occur in cancer patients either as a result of the malignancy or from treatment. In general, a platelet count of at least",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    is adequate for most surgical procedures, but the specific procedure, and the platelet function, must also be considered. Consider postponing surgery until the platelet count has recovered if the thrombocytopenia is treatment-related.",
"   </p>",
"   <p>",
"    Drugs that can interfere with platelet function (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , non-steroidal antiinflammatory agents) should be discontinued long enough prior to surgery to allow for adequate recovery of platelet function. This period will depend upon the specific antiplatelet agent, the surgery, and the patient&rsquo;s other clinical conditions and medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link\">",
"     \"Preoperative assessment of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H323385#H323385\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Platelet function defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NEUROLOGIC STATUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155040\">",
"    <span class=\"h2\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic syndromes that affect neuromuscular function are relatively rare, but are of particular concern in the perioperative period because treatment with anesthetic agents can exacerbate neuromuscular dysfunction, leading to respiratory failure or delayed extubation. Symptoms of Eaton-Lambert syndrome include proximal muscle weakness, diminished or absent deep tendon reflexes, and autonomic neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    .) Treatment of the cancer may occasionally mitigate these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24201/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Screening for brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine imaging of the central nervous system is not mandatory in patients with cancer prior to surgery. However, radiographic imaging of the brain should be considered in the setting of unexplained symptoms referable to the central nervous system. Furthermore, if prophylactic anticoagulation is planned, radiographic screening for brain metastases should be pursued in those patients whose tumors have a propensity to spread to the central nervous system (CNS) and spontaneously bleed, including melanoma, choriocarcinoma, lung, renal cell, breast, and thyroid cancers. The presence of CNS metastases represents a relative contraindication to systemic anticoagulation in this setting, while active intracranial bleeding is an absolute contraindication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulant and antiplatelet therapy in patients with brain tumors\", section on 'Evaluating the risk of bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155047\">",
"    <span class=\"h2\">",
"     Stroke risk in patients undergoing neck irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic stroke can be a late complication of neck irradiation, with multiple factors contributing to this risk, including carotid artery stenosis, increased deposition of plaque, and preexisting risk factors for cerebrovascular disease, such as smoking. A high index of suspicion for carotid artery disease should be maintained in patients who have received neck irradiation, particularly in conjunction with chemotherapy for head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822529#H3822529\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Carotid artery injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER EFFECTS OF CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several chemotherapeutic agents are potentially hepatotoxic. Although most hepatotoxic effects are transient, if signs or symptoms suggest the development of hepatotoxicity, then measure the prothrombin time as a test of adequate hepatic synthetic function prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several chemotherapeutic agents are potentially nephrotoxic, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . For virtually all patients who have recently undergone chemotherapy, measure serum blood urea nitrogen, creatinine, and electrolyte concentrations before surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical risk for most cancer patients is comparable to that of patients without cancer, and should be managed similarly. However, the following should be considered in the preoperative evaluation of patients with cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimize nutritional status prior to surgery. Consider supplemental enteral or parental nutrition for severely malnourished patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Address postoperative pain control during the preoperative evaluation of patients who chronically take opioids, because these patients are likely to require greater than usual doses of medication for postoperative pain control. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have received radiation therapy to fields that include the heart are at increased risk for premature coronary artery disease, cardiac conduction disease, and valvular heart disease. Screen these patients for heart disease clinically and with a 12-lead ECG. Obtain additional cardiac testing if indicated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cardiac status'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Patients who have received anthracycline or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      chemotherapy are at increased risk for heart failure. Screen these patients for heart failure clinically and with a 12-lead ECG. Obtain additional cardiac testing if indicated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiac toxicity from chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Closely monitor patients with asymptomatic malignant pericardial effusions for the development of tamponade in the perioperative period. Treat cardiac tamponade or constrictive pericarditis prior to surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pericardial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mass lesions that could compromise the upper central airway are at increased risk for perioperative respiratory failure. Before surgery, assess the airways of these patients with laryngoscopy.",
"     </li>",
"     <li>",
"      Patients with a mediastinal mass are at increased risk for perioperative cardiopulmonary failure. Before surgery obtain chest CT or MRI, echocardiography, and flow-volume loop measurements. Those with evidence of cardiac, vascular, or central airway compression require special perioperative management. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiopulmonary mass effects'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"      can cause lung damage, and treatment with supplemental inhaled oxygen several years after bleomycin therapy can also cause lung damage. Before surgery, carefully assess the pulmonary function of patients who have ever received bleomycin and during and after surgery minimize the use of supplemental inhaled oxygen in these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"       \"Strategies to reduce postoperative pulmonary complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If time and facilities permit, assess patients at risk for adrenal insufficiency with measurement of an early morning serum cortisol concentration or with an adrenocorticotropin (ACTH) stimulation test. Otherwise, consider treating high-risk patients with empiric perioperative stress-dose glucocorticoid. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Adrenal insufficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"       \"The surgical patient taking glucocorticoids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"       \"Treatment of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measure serum TSH and free T4 concentrations in patients who have ever received neck radiation therapy or who have received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      for more than a few weeks. Correct hypothyroidism prior to surgery. Maintain a high clinical index of suspicion for radiation-induced carotid artery stenosis. &nbsp;(See",
"      <a class=\"local\" href=\"#H1155047\">",
"       'Stroke risk in patients undergoing neck irradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before surgery, screen all patients who have systemic malignancy with serum BUN, creatinine, sodium, and calcium concentrations, and with a complete blood count.",
"     </li>",
"     <li>",
"      When feasible, postpone surgery to allow recovery from chemotherapy-induced neutropenia and thrombocytopenia. &nbsp;(See",
"      <a class=\"local\" href=\"#H23\">",
"       'Neutropenia and lymphopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before surgery, specifically prepare patients with carcinoid or pheochromocytoma. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Carcinoid crisis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Pheochromocytoma surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/1\">",
"      Ramesh HS, Pope D, Gennari R, Audisio RA. Optimising surgical management of elderly cancer patients. World J Surg Oncol 2005; 3:17.",
"     </a>",
"    </li>",
"    <li>",
"     ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart file://www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.185700 (Accessed on April 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/3\">",
"      Morton DL, Kagan AR, Roberts WC, et al. Pericardiectomy for radiation-induced pericarditis with effusion. Ann Thorac Surg 1969; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/4\">",
"      Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/5\">",
"      Stewart JR, Fajardo LF. Radiation-induced heart disease. Clinical and experimental aspects. Radiol Clin North Am 1971; 9:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/6\">",
"      Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991; 99:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/7\">",
"      Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/8\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/9\">",
"      Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982; 9:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/10\">",
"      Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/11\">",
"      Mackie AM, Watson CB. Anaesthesia and mediastinal masses. A case report and review of the literature. Anaesthesia 1984; 39:899.",
"     </a>",
"    </li>",
"    <li>",
"     Mathes DD, Bogdonoff DL. Preoperative evaluation of the cancer patient. In: Surgical Problems Affecting the Patient with Cancer, Lefor AT (Ed), Lippincott-Raven, Philadelphia 1996. p.273.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/13\">",
"      Klein DS, Wilds PR. Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications. Can Anaesth Soc J 1983; 30:399.",
"     </a>",
"    </li>",
"    <li>",
"     Sendak MJ. Monitoring and management of perioperative fluid and electrolyte therapy. In: Principles and Practice of Anesthesiology, Rogers MC, Tinker JH, Covino BG (Eds), Mosby, St. Louis 1992. p.863.",
"    </li>",
"    <li>",
"     Yeung S-CJ, Lazo-Diaz G, Gagel RF. Metabolic and endocrine emergencies. In: Oncologic Emergencies, Yeung SCJ, Escalante C (Eds), BC Decker, Inc, Ontario 2002. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/16\">",
"      Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991; 325:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/17\">",
"      Peerboom PF, Hassink EA, Melkert R, et al. Thyroid function 10-18 years after mantle field irradiation for Hodgkin's disease. Eur J Cancer 1992; 28A:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/18\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/19\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24201/abstract/20\">",
"      McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321:1567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2793 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24201=[""].join("\n");
var outline_f23_40_24201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CARDIAC STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiac assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coronary and cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac toxicity from chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CARDIOPULMONARY MASS EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PULMONARY ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment-related pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ENDOCRINE AND ELECTROLYTE STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Carcinoid crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pheochromocytoma surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HEMATOLOGIC STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hypercoagulability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neutropenia and lymphopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NEUROLOGIC STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1155040\">",
"      Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Screening for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1155047\">",
"      Stroke risk in patients undergoing neck irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER EFFECTS OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11760\" title=\"table 1\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/56/27532\" title=\"table 2\">",
"      ACC AHA prediction periop risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/2/7212\" title=\"table 3\">",
"      ACC AHA CV risk noncard surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_40_24202="Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias";
var content_f23_40_24202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Jami C Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Mark E Alexander, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24202/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/40/24202/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/40/24202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias result from abnormal automaticity, abnormal conduction, or both. Fetal cardiac arrhythmias complicate 1 to 2 percent of pregnancies. They are categorized according to their rhythm (irregular, regular) and rate (tachycardia, bradycardia) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The type and distribution of arrhythmias in one large series are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef60210 \" href=\"UTD.htm?24/27/25019\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fetal arrhythmias will be reviewed here. Diagnosis and management of arrhythmias in neonates and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43623?source=see_link\">",
"     \"Irregular heart rate (arrhythmias) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H270526177#H270526177\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Abnormal heart rate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conduction system of the fetal heart is functionally mature by 16 weeks of gestation, and produces a regular rhythm and rate between 110 and 160 beats per minute (bpm) for the remainder of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/5\">",
"     5",
"    </a>",
"    ]. Fetal arrhythmias are defined by deviations from these parameters. They are typically detected when auscultating the fetal heart, while monitoring the fetal heart rate (FHR) with external or internal devices, or during an antenatal ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H2#H2\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Fetal cardiac development and physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to differentiate fetal arrhythmias, particularly intrapartum, from nonreassuring FHR changes related to hypoxemia or other factors. This distinction is usually obvious because of the clinical circumstances. For example, repetitive bradycardia that begins and ends with (or following) uterine contractions is probably related to hypoxemia, while tachycardia associated with prolonged fetal activity or maternal fever probably reflects a normal physiological response rather than a conduction abnormality. When there are concerns, fetal well-being can be evaluated by assessing the FHR response to fetal stimulation or movement, biophysical profile score, or through umbilical blood gas analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although arrhythmias in children and adults can be evaluated by obtaining an electrocardiogram (ECG), fetal electrocardiography is complicated by difficulty obtaining a signal due to low voltage, background noise, and the inclusion of the maternal electrocardiographic signal during the examination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. At present, ultrasonography is the best modality for evaluation of fetal arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Two-dimensional ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional ultrasound is used to diagnose the specific arrhythmia, evaluate cardiac anatomy, evaluate cardiac function, and look for signs of hydrops fetalis. The cardiac anatomy should be carefully reviewed, as arrhythmias can be associated with congenital heart disease. This risk is about 10 percent in patients with tachycardia and about 50 percent in patients with bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of fluid collections consistent with hydrops is an ominous sign that the arrhythmia has impaired the normal cardiovascular physiology by affecting ventricular filling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonimmune hydrops fetalis\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonimmune hydrops fetalis\", section on 'Cardiovascular abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     M-mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode ultrasonography is used to detect atrial and ventricular wall motion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the motion of the semilunar and atrioventricular valves (",
"    <a class=\"graphic graphic_figure graphicRef80710 \" href=\"UTD.htm?4/10/4262\">",
"     figure 1",
"    </a>",
"    ). It allows determination of the relative timing of cardiac events, thus helping to characterize the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulsed wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed wave Doppler velocimetry can be used to evaluate the relationship of the atrial contractions to the ventricular contractions. This is done by placing the Doppler cursor in the left ventricular outflow tract so that the cursor is parallel to the direction of aortic flow. Once the cursor is lined up, the Doppler gate is widened so that it can sample both left ventricular inflow and outflow at the same time. With this tracing, one can measure the P-R interval and evaluate the timing of the atrial and ventricular contractions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=see_link\">",
"     \"Echocardiography essentials: Physics and instrumentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulsed Doppler can also be used to assess blood flow in the umbilical vein and artery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/9\">",
"     9",
"    </a>",
"    ]. The waveform in the umbilical vessels may be abnormal secondary to changes in intracardiac pressures or the presence of AV valve regurgitation caused by atrial-ventricular dyssynchrony",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"     \"Venous Doppler for fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tissue Doppler Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue Doppler Imaging (TDI) can be utilized to help characterize wall motion. This makes it easier to identify the origin of the arrhythmia and can be quite helpful when other modalities are not diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8167751\">",
"    <span class=\"h2\">",
"     External fetal heart rate monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard FHR monitoring has the advantages of being readily available and able to provide continuous monitoring over long periods of time. However, aliasing at 240 bpm limits its ability to track the most rapid tachycardias and very transient arrhythmias (ie, the internal logic of the monitor may deploy a rate that is half that of the true rate). Despite these limitations, standard FHR monitoring is useful for sustained monitoring of fetuses with slower forms of supraventricular tachycardia (SVT) (eg, atrial flutter) and to determine the proportion of time the fetus is in normal and abnormal rhythms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8167758\">",
"    <span class=\"h2\">",
"     Fetal magnetocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetocardiography shifts the electrical signals into an evoked magnetic signal that can be processed to create a beat-to-beat magnetocardiogram that looks much like a traditional electrocardiogram (ECG). Continuous recordings can be performed for relatively sustained periods and have permitted elegant demonstration of arrhythmia",
"    <span class=\"nowrap\">",
"     onset/offset",
"    </span>",
"    and more direct observation of mechanisms. The equipment is not widely available, requires careful shielding and requires skilled technical support, so the technology remains investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IRREGULAR RHYTHMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irregular rhythms are the most common arrhythmias noted during routine obstetrical evaluation. They are most common in the late second or third trimester, but can present earlier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Premature atrial contractions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of an irregular rhythm in the fetus is premature atrial contractions. In some cases, there is 1:1 conduction of ectopic beats so the ventricular contraction will also be early. On auscultation, the rhythm will sound irregular, but the rate will be nearly normal.",
"   </p>",
"   <p>",
"    In other cases, the premature beat will be blocked so there will be no associated ventricular contraction. In these cases, the ventricular rate will be slower than the atrial rate. When the premature beats are blocked intermittently, the rhythm sounds irregular and the heart rate rapidly varies from normal to slow.",
"   </p>",
"   <p>",
"    Premature atrial contractions are usually benign and intermittent, and may resolve prior to delivery or shortly after birth. However, 1 to 3 percent of fetuses with premature atrial contractions will develop a tachyarrhythmia, which can lead to cardiovascular decompensation. Any fetus with a tachyarrhythmia should be evaluated promptly by a fetal cardiology team.",
"   </p>",
"   <p>",
"    Congenital heart disease is identified in only 0.3 to 2 percent of fetuses with premature atrial beats [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In fetuses with frequent ectopy, the FHR should be evaluated by auscultation or Doppler device at each prenatal visit to exclude conversion to a tachyarrhythmia. The routine schedule of obstetrical follow-up visits is adequate. For purposes of reassurance, more frequent visits (eg, weekly) may be scheduled initially after the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, the mother should be instructed to call if she notes decreased fetal activity, as this may be a sign of fetal tachycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some consultants recommend the mother be evaluated for thyroid disease and advised to decrease consumption of stimulants such as caffeine; however, there are no studies that indicate that thyroid disease or stimulant use contribute to the development of premature contractions in the fetus. We feel these interventions are unnecessary unless clinically indicated because of maternal symptoms.",
"   </p>",
"   <p>",
"    In addition, an obstetrical ultrasound examination should be performed. Since most fetuses do not have significant structural heart disease, a good quality ultrasound is often sufficient. It is important that the ultrasound is done by a sonologist with experience in assessment of cardiac function and structure. Typically, this means an examination that includes color Doppler evaluation of intracardiac and great artery flow. If this evaluation is abnormal, we suggest referral to a fetal cardiology team for a full evaluation of cardiac function and anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Premature junctional and ventricular contractions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature junctional and ventricular contractions are more rare than premature atrial contractions. They are also more difficult to diagnose by echocardiography alone. Premature junctional contractions may be characterized by simultaneous premature atrial and ventricular wall motion. Premature ventricular contractions are characterized by ventricular wall motion, which is not preceded by atrial contraction.",
"   </p>",
"   <p>",
"    Isolated junctional and ventricular premature contractions have a benign prognosis for the fetus. As with premature atrial contractions, cardiovascular compromise can occur if sustained junctional or ventricular tachycardia develops. These cases should be evaluated promptly by a fetal cardiology team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TACHYARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short bursts of sinus tachycardia (typically 160 to 200 bpm) associated with fetal movement are normal in late pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/15\">",
"     15",
"    </a>",
"    ]. Prolonged sinus tachycardia may result from early fetal hypoxia, elevated maternal catecholamine levels due to anxiety or pain, maternal fever or thyrotoxicosis, intraamniotic infection, or maternal administration of beta-adrenergic or vagolytic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/1\">",
"     1",
"    </a>",
"    ]. Although uncommon, benign sinus tachycardia in the fetus has also been described.",
"   </p>",
"   <p>",
"    Evidence of fetal tachycardia should prompt immediate evaluation and consultation with a fetal cardiology team [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The presence of sustained tachyarrhythmia or an intermittent arrhythmia that is frequent and prolonged (occurring &gt;50 percent of the time) puts the fetus at risk for cardiovascular failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/3\">",
"     3",
"    </a>",
"    ]. Early echocardiographic signs of hemodynamic compromise include biatrial enlargement and atrioventricular valve regurgitation; later findings include cardiomegaly and decreased systolic function, ultimately resulting in nonimmune hydrops fetalis. Signs of evolving hydrops include fluid accumulation in pericardial or pleural spaces, ascites, subcutaneous edema, increases in amniotic fluid volume, thickening of the placenta. These signs can appear within 24 hours of onset of sustained tachycardia; therefore, if tachycardia is persistent, re-evaluation for hydrops should occur at frequent intervals, even daily.",
"   </p>",
"   <p>",
"    The goal in managing fetuses with tachyarrhythmias is prevention or resolution of hydrops since the mortality rate of fetuses with arrhythmias and hydrops is over 50 percent, which is far higher than in cases without evidence of significant heart failure. This is achieved with medical therapy, either in utero or postnatally, to convert the tachycardia to sinus rhythm or by slowing the ventricular rate. Individual series report that cardioversion is successful in 65 to 95 percent of cases, within 48 hours to one week of initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/16\">",
"     16",
"    </a>",
"    ]. A summary of these series found that termination of atrial",
"    <span class=\"nowrap\">",
"     flutter/SVT",
"    </span>",
"    before birth occurred in 51 percent of fetuses (115 of 226) treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    as first line-therapy, in 64 percent (45 of 70) of those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    initially, and in 66 percent (23 of 35) of those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    initially [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five to 10 percent of fetuses with pathologic tachycardia have congenital heart disease. Any anatomic abnormality may be present, although there is an increased incidence of Ebstein's anomaly and other causes of atrial enlargement (atrioventricular canal, hypoplastic left heart syndrome, intracardiac tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular tachycardia (SVT) is the most common fetal tachycardia. It is characterized by a regular rate that is typically between 220 and 260 bpm, but rarely may be as high as 300. SVT can be sustained for hours or days, but more commonly is intermittent.",
"   </p>",
"   <p>",
"    The most common mechanism for fetal SVT is a reentrant tachycardia. The most common type is atrioventricular reentrant tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/12\">",
"     12",
"    </a>",
"    ]. It is generally believed",
"    <sup>",
"    </sup>",
"    to be initiated by a critically timed spontaneous premature",
"    <sup>",
"    </sup>",
"    atrial contraction (PAC) and terminated by spontaneous block.",
"    <sup>",
"    </sup>",
"    The PAC causes delayed antegrade conduction through the AV node",
"    <sup>",
"    </sup>",
"    with subsequent retrograde conduction through the accessory",
"    <sup>",
"    </sup>",
"    connection, thus initiating orthodromic reciprocating tachycardia. Fetal magnetocardiography can be helpful in understanding the underlying mechanism of the arrhythmia, but is available in only a few centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progression to ventricular dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hydrops fetalis depends on the duration of SVT, more than the rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11149956\">",
"    <span class=\"h3\">",
"     Approach to management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management approach to SVT depends upon the fetal condition and gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Typically, the obstetrical staff and the pediatric cardiology staff will develop a treatment plan, ideally including a pediatric electrophysiologist and often an adult-oriented electrophysiologist.",
"   </p>",
"   <p>",
"    Multiple case series have reported a variety of approaches to management of fetal SVT; however, no controlled therapeutic trials have been performed. Options include observation alone, delivery and postnatal management, in utero therapy via maternal administration of drugs, and in utero therapy via direct fetal injection. Fetal intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    injection has been safe and effective in some cases. However, we do not advise direct umbilical artery or vein digoxin injection because of the increased risk of fetal mortality, which may be procedure-related, due to the poor underlying cardiovascular condition in these cases, or a combination of these factors.",
"   </p>",
"   <p>",
"    The following factors that influence the management approach are also summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef68843 \" href=\"UTD.htm?15/33/15900\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tachycardia rate",
"      </strong>",
"      &ndash; Rates &gt;220 bpm are most likely to progress to hydrops, rates &lt;200 to 220 bpm are much less likely to have hemodynamic consequences.",
"     </li>",
"     <li>",
"      <strong>",
"       Persistence of the tachycardia",
"      </strong>",
"      &ndash; SVT present &gt;50 percent of the day is likely to lead to hydrops whereas tachycardia &lt;20 percent of the day is usually well-tolerated. Intermittent short bursts of tachycardia are very well tolerated and do not mandate treatment. Follow-up should be individualized based on the frequency and duration of the episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Gestational age",
"      </strong>",
"      &ndash; Delivery for postnatal treatment is preferable as gestational age increases and prematurity risks decrease.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Presence/absence",
"       </strong>",
"      </span>",
"      of hydrops",
"      &ndash; Prior to pulmonary maturity, sonographic evidence of developing hydrops mandates treatment to slow the FHR and improve cardiac performance. Delivery followed by postnatal treatment is less desirable in this setting because the combination of hydrops and prematurity is associated with very high morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/22\">",
"       22",
"      </a>",
"      ]. Nonhydropic preterm fetuses with frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      long periods of SVT are often treated since successful cardioversion is less likely after hydrops has developed.",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital heart disease",
"      </strong>",
"      &ndash; If structural anomalies are present, the postnatal management and prognosis of these anomalies need to be taken into account.",
"     </li>",
"     <li>",
"      <strong>",
"       Maternal factors &ndash;",
"      </strong>",
"      Preeclampsia or mirror syndrome places the mother at risk of severe sequelae, and is an indication for intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11149987\">",
"    <span class=\"h3\">",
"     Initial maternal and fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating therapy, maternal assessment should include medical history (especially cardiac history), medication history, ECG, blood pressure, and laboratory tests (serum electrolytes, tests of renal and hepatic function, urine protein, and platelet count).",
"   </p>",
"   <p>",
"    An initial period of fetal observation to document baseline status is warranted before beginning drug therapy. A reasonable approach is to admit the patient to the labor or antepartum unit and either obtain frequent Doppler FHR assessments (eg, hourly when the mother is",
"    <span class=\"nowrap\">",
"     awake/every",
"    </span>",
"    two hours when she is asleep) or perform continuous external fetal monitoring when technically possible, as in the slower tachycardias. Fetal assessment can be done while performing the maternal medical and obstetrical assessment, and possibly coincident with an initial drug loading.",
"   </p>",
"   <p>",
"    For the nonhydropic fetus with a healthy mother, slowly initiate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    orally as an outpatient; however, most other antiarrhythmic drugs are initiated with inpatient maternal monitoring, including daily ECGs. For therapies other than digoxin or beta-blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ), continuous cardiac monitoring is the current practice in the US for patients undergoing medical cardioversion and a reasonable approach in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11149994\">",
"    <span class=\"h3\">",
"     Drug treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplacental therapy is the mainstay of fetal tachycardia management, unless there is some unusual contraindication to giving the mother medication. Many medications have the potential to break SVT; they differ in their side effects and their ability to cross the placenta. In general, they all have a lower success rate in fetuses with hydrops, likely due to lower transplacental transfer. There are no standards for drug dosing, the need for loading doses, and whether the mother should be hospitalized when therapy is initiated. Drug dosing is empiric and depends on maternal, as well as fetal, factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2595640\">",
"    <span class=\"h4\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on its safety profile and efficacy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is the initial drug of choice, either administered orally or intravenously to the mother or, if unsuccessful, via direct intramuscular fetal injection. As discussed above, a literature review found that termination of atrial",
"    <span class=\"nowrap\">",
"     flutter/SVT",
"    </span>",
"    before birth occurred in 51 percent of fetuses (115 of 226) treated with digoxin as first line-therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presuming normal maternal renal function, a reasonable oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    loading dose for rapid loading is 1 to 2 mg, which can be given in three doses: 0.5 mg, 0.25 mg, and 0.25 mg over 18 to 24 hours, followed by a digoxin level. Additional doses are given if the digoxin level is low. The target level is 1 to 2",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    After this target is achieved, it may take an additional 24 hours before fetal serum levels reach a steady state, so a period of observation to assess the fetal response to maximum maternal therapy is reasonable. Once the target (therapeutic) maternal serum level is achieved, the risk of maternal toxicity from additional dose increases likely outweighs any fetal benefits of supratherapeutic maternal digoxin levels.",
"   </p>",
"   <p>",
"    <br/>",
"    The maternal maintenance dose is then determined by titrating to the fetal response, which might take several days. Close inpatient maternal monitoring is mandatory to avoid maternal toxicity (gastrointestinal and central nervous system disturbances, arrhythmias including premature beats and atrioventricular [AV] block). Daily ECGs to monitor for P-R prolongation and T wave changes are required when rapid loading is performed; continuous cardiac monitoring is not usually done. With slower or nonsustained arrhythmias, a slower outpatient course of drug initiation and maintenance is appropriate.",
"    <br/>",
"    <br/>",
"    Maintenance dosing usually needs to be higher in pregnant women than nonpregnant women because of increases in blood volume and glomerular filtration rates associated with pregnancy, often ranging from 0.5 to 0.75 mg daily given in divided doses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    levels can be obtained rapidly in most facilities, which permits relatively timely dose adjustments.",
"    <br/>",
"   </p>",
"   <p>",
"    When the fetus is hydropic, it is less likely to respond and higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    may be given [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/3,23,24\">",
"     3,23,24",
"    </a>",
"    ]. It is important to closely monitor the maternal ECG and digoxin levels to avoid maternal toxicity.",
"   </p>",
"   <p>",
"    Direct fetal intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is another approach which has been used to achieve therapeutic fetal drug levels, particularly in the hydropic fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/25\">",
"     25",
"    </a>",
"    ]. Fetal intramuscular therapy can be combined with",
"    <span class=\"nowrap\">",
"     maternal/transplacental",
"    </span>",
"    therapy. Drug treatment in this setting is beyond the scope of this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11150008\">",
"    <span class=\"h4\">",
"     Flecainide, sotalol, amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the fetal condition is not improving or is deteriorating despite adequate maternal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    levels (1 to 2",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    other medications should be considered.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    are the most popular second-line therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/22,23,26-34\">",
"     22,23,26-34",
"    </a>",
"    ]; flecainide and sotalol have also been used first-line [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/17\">",
"     17",
"    </a>",
"    ]. Because of maternal risks associated with the use of these medications, we do not use them as first-line agents and carefully consider their risks and benefits when deciding which second-line therapy to try.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    has also been used; however, there are concerns about cardiovascular collapse in fetuses and infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/26\">",
"     26",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/3\">",
"     3",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    are no longer readily available; the anticipated maternal risks of quinidine are higher than with the alternative drugs.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    fails (sustained SVT, hydrops), some specialists advocate adding a second drug, while others suggest discontinuing the digoxin when starting the second drug. Different institutions have published single center data looking at their experience with second-line therapies in hydropic fetuses, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/30,31\">",
"     30,31",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/26,27,29\">",
"     26,27,29",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (both as a second-line agent or after failure of sotalol or flecainide) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/23,28,33\">",
"     23,28,33",
"    </a>",
"    ]. Because none of these drugs have been evaluated in randomized trials, there are no strong data favoring one drug or combination over another. Case reports suggest that all of these alternative therapies may be effective both singly and in combination with digoxin. All of the treatments appear to be safe, although careful monitoring for maternal toxicity is important. Sotalol and flecainide can be proarrhythmic in certain settings, so it is important to have an accurate diagnosis of the arrhythmia, and to monitor both the fetus and the mother carefully.",
"    <br/>",
"    <br/>",
"    The balance of the evidence suggests a slightly higher conversion rate of SVT with flecainide and a slightly higher conversion rate of atrial flutter with sotalol. Relatively few patients have been treated and reported so these conclusions are tentative. Flecainide has the advantage of not having beta-blockade effects. Serum levels can be obtained, although it may take several days before the results are available. Sotalol is a potent beta-blocker in addition to its potassium channel blockade, and is more likely to induce dose dependent beta-blocker side effects.",
"   </p>",
"   <p>",
"    Dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (50 mg, 100 mg, and 150 mg tablets; pregnancy class C) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (80 mg, 120 mg, and 160 mg tablets; pregnancy class B) are similar; both are cleared by the kidney. While twice daily dosing is typical in nonpregnant patients, three times daily dosing is appropriate during pregnancy, given enhanced renal clearance. Fetal demise has been reported in patients receiving these drugs; details are sparse and death could have been due to the disease, not the treatment. There is no intravenous formulation of either drug in the United States.",
"   </p>",
"   <p>",
"    With use of either drug, the pregnant woman is monitored with continuous cardiac monitoring for 48 hours or for the first five to six doses and with daily ECGs; intermittent FHR monitoring is also performed. An initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    80 mg three times per day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    100 mg three times per day or 100 mg, 50 mg, 100 mg over one day (ie, 250 to 300 mg per day) is reasonable. Expected effects on the tachycardia include increasing frequency of terminations and slowing of the tachycardia rate. Decisions about dose increases or drug changes can be made every 48 to 72 hours based on the fetal effects and maternal ECGs. If there is no change, then one to two incremental increases in dose should be attempted prior to switching to an alternative agent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has been reported to be very successful for fetuses with refractory tachycardia, all of whom failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and most of whom had persistent arrhythmia despite a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/23\">",
"     23",
"    </a>",
"    ]. While there has been concern about delayed placental transport in hydropic fetuses, a strategy of initial loading to a total of 12 to 13 grams led to conversion to sinus rhythm at a mean of six days. Thyroid function (in both the fetus and mother) needs to be monitored, and treated if necessary. Amiodarone has a long half-life and has been associated with neonatal hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link&amp;anchor=H5990251#H5990251\">",
"     \"Clinical uses of amiodarone\", section on 'Use in pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11150015\">",
"    <span class=\"h4\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the tachycardia is controlled, close outpatient monitoring is important. This typically includes a plan of daily fetal kick counts and frequent prenatal visits (two to three times per week) with nonstress tests or biophysical profile scores weekly. ECGs and serum drug levels should be obtained every one to two weeks when the mother is seen for prenatal care or fetal testing. If the mother appears to be developing preeclampsia, all drugs except",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    should be discontinued or have their doses decreased if there is evidence of renal insufficiency related to preeclampsia. The fetus should be evaluated for any suggestion of worsening hydrops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H6#H6\">",
"     \"Nonimmune hydrops fetalis\", section on 'Mirror syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After several weeks of controlled sinus rhythm or as the fetus approaches term, an attempt to taper medications (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in particular) can help limit neonatal side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11150022\">",
"    <span class=\"h4\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viable fetuses unresponsive to treatment and those with pulmonary maturity may be best served by delivery for further evaluation and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/22\">",
"     22",
"    </a>",
"    ]. Decisions about delivery should be made after consultation with a neonatologist and pediatric cardiologist; consultation with an experienced center may permit delay in delivery and limit the consequences of prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844638\">",
"    <span class=\"h3\">",
"     Clinical vignettes",
"    </span>",
"   </p>",
"   <p>",
"    The following clinical vignettes illustrate two examples of treatment approaches.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A healthy G1P0 presented with short runs of nonsustained fetal SVT at 18 weeks of gestation. Fetal echo demonstrated no structural abnormalities, short runs of 1:1 tachycardia at 270 to 300 bpm and frequent extrasystoles, which were interpreted as single beats of tachycardia. Although the SVT was of short duration, due to the elevated rate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      was initiated by giving the mother 0.25 mg, 0.125 mg, 0.25 mg orally over one day as an outpatient, with resolution of the arrhythmia within several days. Maternal digoxin levels were 1 to 1.2",
"      <span class=\"nowrap\">",
"       ng/mL.",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      patient did not return for scheduled follow-up care and re-presented at 24 weeks with a hydropic fetus with sustained tachycardia at 270 bpm, 1:1 AV relationships. Maternal blood work confirmed compliance with her digoxin regimen. The digoxin was continued and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      was initiated at 100 mg three times daily and increased to 150 mg three times daily with continuous maternal ECG monitoring. Over six days, there was no change in fetal status. Flecainide levels were 0.48 and 1.0 (upper limit of normal 1.0), at which time flecainide was discontinued.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      240",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (80 mg three times daily) was begun and the dose increased to 480",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (160 three times daily) over four days. Tachycardia transiently terminated at 48 hours, with complete termination by day 4. Ventricular function in sinus rhythm was excellent with improvement of the fetal hydrops within two days, but some residual ascites remained for nearly two weeks.",
"      <br/>",
"      <br/>",
"      At birth, the infant had Wolf-Parkinson White (WPW) syndrome with preexcitation on her ECG and recurrent SVT. This was controlled medically for several years prior to a successful catheter ablation.",
"     </li>",
"     <li>",
"      A 35-year-old G1P0 presented at 24 weeks of gestation with sustained fetal SVT at 250 bpm with 1:1 conduction by M-mode, mild ascites, and moderately depressed ventricular function.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      0.5 mg, 0.25 mg and 0.25 mg was initiated over the first 12 hours. The digoxin level was 0.7",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and the dose adjusted to a maintenance dose of 0.125 mg, 0.25 mg, 0.125 mg per day, which resulted in a digoxin level of 1.4",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      however, sustained tachycardia remained and there was evidence of hydrops.",
"      <br/>",
"      <br/>",
"      Digoxin was continued and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      80 mg three times daily was initiated without significant change in the FHR over five doses. Sotalol was increased to 320",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and then 480",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      with resolution of the SVT two doses after the increase to 480",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The hydrops also resolved promptly.",
"      <br/>",
"      <br/>",
"      At 31 weeks, the mother had an episode of vasodepressor syncope attributed, in part, to excessive beta-blockade and resting systolic blood pressures in the 90s. Sotalol was decreased to 160 mg, 80 mg, 160 mg per day, with prompt recurrence of nonsustained SVT, which resolved with return to sotalol 480",
"      <span class=\"nowrap\">",
"       mg/day.",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      patient was induced at 37 weeks of gestation because of decreased diastolic flow on umbilical artery Doppler. The infant was observed off therapy, but at 10 days he presented with recurrent, sustained SVT with evidence of WPW syndrome that has been controlled with oral sotalol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atrial flutter and fibrillation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844612\">",
"    <span class=\"h3\">",
"     Atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter is less common than SVT and tends to occur at a later gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/40\">",
"     40",
"    </a>",
"    ]. It is characterized by extremely fast, regular atrial rates (400 to 500 bpm) with a slower, but regular, ventricular rate (very fixed ventricular rates of 200 to 220 bpm without spontaneous terminations). Typically, there is 2:1, 3:1, or 4:1 atrio-ventricular block, producing a ventricular rate that may be tachycardic, but may also be within the normal range. By auscultation, atrial flutter with 3:1 or 4:1 block may not be recognized since the ventricular rate may be normal. In flutter, the ventricular rate is usually fixed and does not change with fetal activity. This may be the only sign on auscultation that the rhythm is abnormal. Postnatal experience with atrial flutter suggests that nearly 20 percent of affected fetuses will also have SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is extremely rare in the fetus and, in the absence of significant AV valve disease, an alternative explanation should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Management of atrial flutter and fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data from randomized trials to guide therapy, which is largely based on experience and data from small series and case reports. Atrial flutter can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    to slow the ventricular response rate, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    to restore normal sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/3,24,30,31,42\">",
"     3,24,30,31,42",
"    </a>",
"    ]. As discussed above, a literature review found that termination of atrial",
"    <span class=\"nowrap\">",
"     flutter/SVT",
"    </span>",
"    before birth occurred in 51 percent of fetuses (115 of 226) treated with digoxin as first line-therapy, in 64 percent (45 of 70) of those treated with flecainide initially, and in 66 percent (23 of 35) of those treated with sotalol initially [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    has traditionally been the first-line treatment of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11150552\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia and fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia and fibrillation are rarely diagnosed in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. By definition, ventricular rates are over 200 bpm. M-mode will show complete dissociation of atrial and ventricular contraction with an atrial rate that is slower than the ventricular rate. Ventricular tachycardia is usually paroxysmal and may be associated with myocarditis, complete heart block, or congenital long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/18\">",
"     18",
"    </a>",
"    ]. The prognosis depends on the underlying mechanism.",
"   </p>",
"   <p>",
"    The rarity of fetal ventricular tachycardia means that there is no consensus about optimal therapy; expectant management of stable fetuses has been described with spontaneous resolution of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/43\">",
"     43",
"    </a>",
"    ]. Successful treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     BRADYARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal bradycardia is defined as an intermittent or persistent FHR less than 110 bpm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/5\">",
"     5",
"    </a>",
"    ]. In the absence of labor, the most common causes of a sustained slow heart rate are complete heart block, sinus bradycardia, and blocked atrial bigeminy. A persistent ventricular rate &lt;60 bpm is usually associated with complete heart block, while rates between 60 and 80 bpm can be due to nonconducted bigeminy or second or third degree block, and rates of 100 to 110 bpm are usually due to sinus bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In complete (third degree) heart block, there is complete dissociation of the atrial and ventricular rates because there is no atrio-ventricular conduction. The atrial rate is typically normal and the ventricular rate is typically between 50 and 80 bpm, but can be lower or higher. The rate may slow as the pregnancy progresses, so regular evaluation of heart rate and ventricular function is important.",
"   </p>",
"   <p>",
"    Complete heart block is associated with congenital heart disease in about 50 percent of patients, so a complete anatomic evaluation should be performed in all fetuses with heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/45\">",
"     45",
"    </a>",
"    ]. While any type of heart disease can be present, the most common lesions are L-transposition of the great arteries and certain types of heterotaxy, particularly those associated with polysplenia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Other causes of complete heart block include exposure to maternal lupus autoantibodies and myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link&amp;anchor=H11717418#H11717418\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\", section on 'Neonatal lupus syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    death is particularly high in fetuses with heart block associated with structural heart disease, endocardial fibroelastosis (see below), or hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/46-50\">",
"     46-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to distinguish complete heart block from a bradycardic rhythm due to multiple blocked atrial ectopic beats, as the latter is benign. The distinction can be made by assessing the atrial rhythm; in complete heart block, the atrial rhythm should be regular, whereas in atrial ectopy, the atrial rhythm will be irregular due to the presence of the premature beats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a fetus with a structurally normal heart is diagnosed with heart block, maternal blood should be sampled for",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies (if not already known to be present). These autoantibodies are thought to induce fetal myocarditis and destruction of the conducting fibers in the fetal, but not maternal, heart. The hearts of fetuses exposed to these antibodies have normal morphology, but may develop endocardial fibroelastosis and dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the fetus with complete atrioventricular (AV) block is primarily expectant. Fetuses generally tolerate the arrhythmia well when ventricular rates are greater than 55 bpm in the absence of anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/2,45\">",
"     2,45",
"    </a>",
"    ]. There have been attempts to increase the FHR with maternal administration of beta-adrenergic agents or with pacemaker leads placed into the fetal heart. Acute therapy with beta-agonists results in an approximately 10 percent increase in heart rate and stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/51\">",
"     51",
"    </a>",
"    ]. Administration of maternal beta-agonist therapy when the FHR is &lt;50 to 55 bpm has been advocated, though this approach has not been evaluated by comparative studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    has been prescribed for fetuses with prolonged PR intervals in an effort to prevent progression to complete heart block (see below). It has also been used in an attempt to treat complete heart block. While there are some cases of successful treatment, the bulk of evidence suggests that steroids cannot reverse third degree block, but may prevent progression of the rarely recognized second degree block to complete block. Steroids have also been used to ameliorate hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/53\">",
"     53",
"    </a>",
"    ]. The effect on first degree block is controversial and is discussed below.",
"   </p>",
"   <p>",
"    At the time of labor, it is possible to monitor fetal well-being using the atrial rate as detected by Doppler devices normally used in fetal monitoring. A normal atrial rate with normal heart rate variability is reassuring. It is also possible to perform serial biophysical profile assessments or fetal pH measurements, if these resources are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pacemaker after birth is always required, but may not be necessary for several years. Among women with anti-SSA and anti-SSB antibodies and a prior child who developed heart block, recurrence is common (about 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H646776944\">",
"    <span class=\"h3\">",
"     Prevention in fetuses of women with anti-lupus autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block occurs in approximately 1 to 2 percent of pregnancies of women with anti-lupus autoantibodies; the risk is higher in women with high titers. Congenital heart block occurs in 15 percent of subsequent pregnancies of mothers who have given birth to a previously affected child. For pregnancies in which the FHR is normal and the mother has known anti-lupus autoantibodies, some experts suggest frequent (weekly) ultrasound screening from about 16 to 24 weeks to look for lengthening of the P-R interval. Heart block is less likely to present after 24 weeks, so the frequency of screening may be decreased to every other week in the third trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link&amp;anchor=H10#H10\">",
"     \"Neonatal lupus\", section on 'Heart block'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link&amp;anchor=H5#H5\">",
"     \"Congenital third degree (complete) atrioventricular block\", section on 'Presentation in utero'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best way to measure the P-R interval is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Inflow/outflow",
"    </span>",
"    Doppler has been used by some investigators, while others have found that a combination of venous and arterial signals is preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild AV prolongation may not progress and is likely to resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/57\">",
"     57",
"    </a>",
"    ]. If the P-R interval lengthens significantly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    has been initiated in an effort to avoid progression to complete heart block, although the efficacy of this approach is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/7,52,53,58-62\">",
"     7,52,53,58-62",
"    </a>",
"    ]. The most recent studies failed to demonstrate any reversal of heart block and reported smaller infants with chronic maternal steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/53,59\">",
"     53,59",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Two trials including a total of 44 pregnancies used IVIG 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    beginning at 12 weeks of gestation to prevent complete heart block in at risk mothers; however, this therapy was unsuccessful in preventing the recurrence of complete heart block or reducing maternal antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    as a prevention strategy in mothers with previously affected infants appears promising and is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sinus bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia refers to a cardiac rhythm of less than 100 bpm in which the atria and ventricles are beating at the same rate. The electrical impulse originates in the sinus node and is normally conducted. Short episodes of sinus bradycardia, especially in the second trimester fetus, are common and physiologic. They may be due to transient fetal head or umbilical cord compression.",
"   </p>",
"   <p>",
"    New-onset sinus bradycardia can be secondary to maternal hypotension, maternal seizures, paracervical block anesthesia, or impaired fetal oxygenation, which can result from conditions including, but not limited to, abruptio placenta, uterine rupture, prolapsed umbilical cord, fetal hemorrhage, and fetal hypotension. Under these circumstances, a poor outcome may result if the cause of the fetal distress cannot be corrected. However, sustained sinus bradycardia may also be associated with structural cardiac anomalies or long Q-T syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/13,14,68\">",
"     13,14,68",
"    </a>",
"    ]. In these situations, it is typically less worrisome because it is not a sign of fetal distress. In the healthy pregnancy with fetal sinus bradycardia, the most common explanation is heterotaxy. The bradycardia is thought to be due to a primary abnormality of the sinus node. The actual structural heart disease may be quite mild (eg, interrupted IVC), or can be very complex (single ventricle heart disease).",
"   </p>",
"   <p>",
"    It is possible for fetuses to tolerate heart rates in the 70 to 90 bpm range over a long period of time, including fetuses with structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/4\">",
"     4",
"    </a>",
"    ]. As in complete heart block, weekly obstetrical follow-up with assessment of fetal well-being is recommended. Alternative methods of evaluation of fetal well-being, such as heart rate variability, umbilical artery Doppler flow, or biophysical profile assessments, may be of assistance in these cases. The timing of periodic evaluation of ventricular function, including an assessment of atrioventricular valve regurgitation and umbilical vessel flow, is individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nonconducted bigeminy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When premature atrial beats occur in bigeminy (or trigeminy) and are consistently blocked, one will hear a regular rhythm that remains slow (65 to 90 bpm). Typically, this is a benign and transient arrhythmia, but it can mimic the auscultatory findings of complete heart block or 2:1 AV block. Recurrent abrupt shifts from heart rates of approximately 60 to 80 bpm to 120 to 160 bpm suggest the presence of blocked atrial premature beats during the bradycardic periods.",
"   </p>",
"   <p>",
"    Two-dimensional imaging, Doppler of the mitral valve inflow, or M-mode of the atrial wall are important for making the correct diagnosis and will show atrial contractions at irregular intervals if the bradycardia is due to blocked premature atrial beats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     2:1 AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to blocked premature atrial contractions, 2:1 block is rare, is characterized by regular atrial-atrial intervals on echocardiography, and is often associated with structural heart disease or maternal autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/61\">",
"     61",
"    </a>",
"    ]. Severe cases of long Q-T syndrome can result in 2:1 block secondary to extremely long ventricular refractory periods [",
"    <a class=\"abstract\" href=\"UTD.htm?23/40/24202/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus with an arrhythmia can undergo labor and be delivered vaginally as long as fetal well-being can be monitored in some way. Fetuses with intermittent arrhythmias may display a normal pattern frequently enough to allow the clinician to be reassured of fetal well-being. If fetal well-being cannot be evaluated, then cesarean delivery is the best option. Although sustained tachycardia, particularly supraventricular tachycardia, is rarely life-threatening during delivery, it is important to try and convert the rhythm as soon as possible after delivery.",
"   </p>",
"   <p>",
"    Optimally, if sustained tachycardia is present, either cardiology or pediatrics specialists should be available at the time of delivery to help with diagnosis and therapeutic decision-making. For bradycardic fetuses, delivery is typically uneventful and the heart rate is adequate to support cardiac output. In a small percentage of cases, the heart rate can drop dramatically after birth, resulting in poor cardiac output. Even in those infants whose heart rate does not change much, cardiac output can be insufficient to support systemic perfusion once the low resistance placenta is gone. It is important that an experienced clinician who is comfortable",
"    <span class=\"nowrap\">",
"     treating/pacing",
"    </span>",
"    newborns with symptomatic bradycardia be available at the time of delivery. In patients with significant congenital heart disease or ventricular dysfunction, all of these concerns are amplified.",
"   </p>",
"   <p>",
"    Transferring the mother to a comprehensive center for delivery may be preferable to emergent local delivery, as the in utero environment is generally more favorable to the fetus with any arrhythmia. When delivery occurs, having a full neonatal cardiac care team available immediately minimizes the time to effective therapy for the newborn, and provides the family close contact with the",
"    <span class=\"nowrap\">",
"     neonatal/pediatric",
"    </span>",
"    ICU, which can facilitate ongoing care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal fetal cardiac activity consists of a regular rhythm with a rate that varies between 100 and 180 beats per minute (bpm). Fetal arrhythmias are defined by deviations from these parameters. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal arrhythmias must be distinguished from fetal heart rate (FHR) changes in response to hypoxia. When a fetal cardiac arrhythmia is suspected, we suggest use of fetal M-mode echocardiography, two-dimensional ultrasonography, and Doppler velocimetry to better define the rhythm and to look for associated cardiac anomalies. For heart rates &lt;240 beats per minute, standard external fetal monitoring allows longer term observation and may detect abrupt changes in heart rate, which may clarify suspected diagnoses. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premature atrial contractions are the most common cause of an irregular rhythm and are generally benign. They often resolve prior to delivery and are rarely associated with significant structural heart disease. Blocked atrial bigeminy can sometimes mimic heart block. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Premature atrial contractions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tachycardia can be due to fetal stress or abnormal conduction. While short bursts of sinus tachycardia (typically 160 to 200 bpm) can be associated with fetal movement in late pregnancy, prolonged tachycardia is always abnormal. Sinus tachycardia may result from early fetal hypoxia, elevated maternal catecholamine levels due to anxiety or pain, maternal fever, intraamniotic infection, or maternal administration of beta-adrenergic or vagolytic drugs. Pathological tachyarrhythmias include supraventricular tachycardia (SVT), atrial flutter, atrial fibrillation, and ventricular tachycardia, with reentrant forms of SVT being the most common. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Tachyarrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermittent short bursts of tachycardia &le;250 bpm are generally well tolerated. For fetuses with intermittent short bursts of tachycardia &le;250 bpm, we suggest expectant management with close follow-up rather than intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11149956\">",
"       'Approach to management'",
"      </a>",
"      above.) For preterm fetuses with sustained SVT or a very high heart rate and pulmonary immaturity, we suggest medical treatment rather than expectant management or delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For the fetus with sustained SVT, pulmonary immaturity and no evidence of hydrops, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We aim for maternal digoxin levels of 1 to 2",
"      <span class=\"nowrap\">",
"       ng/mL.",
"       <br/>",
"       <br/>",
"       If",
"      </span>",
"      the fetus does not improve or deteriorates despite adequate maternal digoxin levels (1 to 2",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      we suggest a trial of other medications, ideally in consultation with pediatric cardiac electrophysiologists.",
"      <br/>",
"      <br/>",
"      For fetuses with sustained SVT and pulmonary maturity, we suggest delivery rather than expectant management or in utero therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Atrial flutter can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      to slow the ventricular response rate, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      to restore normal sinus rhythm.",
"     </li>",
"     <li>",
"      For treatment of atrial fibrillation, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, atrial fibrillation is quite rare in fetuses and the diagnosis should be made carefully. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of atrial flutter and fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradycardia may be due to consistently blocked premature contractions, complete heart block or sinus bradycardia. Heart block and sinus bradycardia are more likely to be associated with structural heart disease than tachyarrhythmias. A short burst of sinus bradycardia is a normal physiologic finding, but sustained bradycardia requires further evaluation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Bradyarrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a fetus is diagnosed with complete heart block, maternal blood should be sampled for",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies. In addition, a complete anatomic survey should be done to exclude structural heart disease, particularly forms of heterotaxy. Treatment of the fetus with complete atrioventricular (AV) block is primarily expectant. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Complete heart block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      positive women whose fetuses have incomplete heart block (mechanical AV interval &gt;~150 msec or second degree AV block), we suggest a short course of maternal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While dexamethasone does not reverse complete AV block, it may ameliorate hydrops, which has a high mortality rate. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Complete heart block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged sinus bradycardia is nonreassuring. Causes include maternal hypotension, maternal seizures, paracervical block anesthesia, and impaired fetal oxygenation (eg, abruptio placenta, uterine rupture, prolapsed umbilical cord). It may also be due to fetal cardiac disease such as heterotaxy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      long Q-T syndrome. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Sinus bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fetus with a sustained arrhythmia can undergo labor and be delivered vaginally as long as fetal well-being can be monitored in some way. We suggest that appropriate support personnel from pediatrics, neonatology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiology be available at the time of the delivery. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If antepartum treatment is initiated, potential maternal toxicity must be monitored, and collaborative care including obstetrics, pediatric cardiology and often an adult cardiologist is needed. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/1\">",
"      Shenker L. Fetal cardiac arrhythmias. Obstet Gynecol Surv 1979; 34:561.",
"     </a>",
"    </li>",
"    <li>",
"     McCurdy CM, Reed KL. Fetal Arrhythmias. In: Doppler Ultrasound in Obstetrics and Gynecology, Copel JA, Reed KL (Eds), Raven Press, New York 1995. p.253.",
"    </li>",
"    <li>",
"     Kleinman CS, Nehgme R, Copel JA. Fetal cardiac arrhythmias: diagnosis and therapy. In: Maternal-Fetal Medicine, 4th ed, Creasy RK, Resnik R (Eds), WB Saunders Co, Philadelphia 1999. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/4\">",
"      Fouron JC. Fetal arrhythmias: the Saint-Justine hospital experience. Prenat Diagn 2004; 24:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/5\">",
"      Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/6\">",
"      Taylor MJ, Smith MJ, Thomas M, et al. Non-invasive fetal electrocardiography in singleton and multiple pregnancies. BJOG 2003; 110:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/7\">",
"      Simpson JM. Fetal arrhythmias. Ultrasound Obstet Gynecol 2006; 27:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/8\">",
"      Reed KL, Sahn DJ, Marx GR, et al. Cardiac Doppler flows during fetal arrhythmias: physiologic consequences. Obstet Gynecol 1987; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/9\">",
"      Indik JH, Chen V, Reed KL. Association of umbilical venous with inferior vena cava blood flow velocities. Obstet Gynecol 1991; 77:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/10\">",
"      Rein AJ, O'Donnell C, Geva T, et al. Use of tissue velocity imaging in the diagnosis of fetal cardiac arrhythmias. Circulation 2002; 106:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/11\">",
"      Zhao H, Chen M, Van Veen BD, et al. Simultaneous fetal magnetocardiography and ultrasound/Doppler imaging. IEEE Trans Biomed Eng 2007; 54:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/12\">",
"      Wakai RT, Strasburger JF, Li Z, et al. Magnetocardiographic rhythm patterns at initiation and termination of fetal supraventricular tachycardia. Circulation 2003; 107:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/13\">",
"      Boldt T, Eronen M, Andersson S. Long-term outcome in fetuses with cardiac arrhythmias. Obstet Gynecol 2003; 102:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/14\">",
"      Copel JA, Liang RI, Demasio K, et al. The clinical significance of the irregular fetal heart rhythm. Am J Obstet Gynecol 2000; 182:813.",
"     </a>",
"    </li>",
"    <li>",
"     Allan LD. Fetal arrhythmias. In: Fetal and Neonatal Cardiology, Long WA (Ed), WB Saunders, 1989. p.180.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/16\">",
"      Simpson LL. Fetal supraventricular tachycardias: diagnosis and management. Semin Perinatol 2000; 24:360.",
"     </a>",
"    </li>",
"    <li>",
"     Jaeggi E, Tulzer G. Pharmacological and interventional fetal cardiovascular treatment. In: Anderson RH, Baker EJ, Redington A, Rigby ML, Penny D, Wernovsky G, eds. Paediatric Cardiology. 3rd ed. Philadelphia, PA: Elsevier; 2009:199 &ndash;218.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/18\">",
"      Strasburger JF. Prenatal diagnosis of fetal arrhythmias. Clin Perinatol 2005; 32:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/19\">",
"      van Engelen AD, Weijtens O, Brenner JI, et al. Management outcome and follow-up of fetal tachycardia. J Am Coll Cardiol 1994; 24:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/20\">",
"      Cuneo BF, Strasburger JF. Management strategy for fetal tachycardia. Obstet Gynecol 2000; 96:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/21\">",
"      Simpson JM, Milburn A, Yates RW, et al. Outcome of intermittent tachyarrhythmias in the fetus. Pediatr Cardiol 1997; 18:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/22\">",
"      van den Heuvel F, Bink-Boelkens MT, du Marchie Sarvaas GJ, Berger RM. Drug management of fetal tachyarrhythmias: are we ready for a systematic and evidence-based approach? Pacing Clin Electrophysiol 2008; 31 Suppl 1:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/23\">",
"      Strasburger JF, Cuneo BF, Michon MM, et al. Amiodarone therapy for drug-refractory fetal tachycardia. Circulation 2004; 109:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/24\">",
"      Krapp M, Kohl T, Simpson JM, et al. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart 2003; 89:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/25\">",
"      Parilla BV, Strasburger JF, Socol ML. Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. Am J Perinatol 1996; 13:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/26\">",
"      Frohn-Mulder IM, Stewart PA, Witsenburg M, et al. The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. Prenat Diagn 1995; 15:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/27\">",
"      Krapp M, Baschat AA, Gembruch U, et al. Flecainide in the intrauterine treatment of fetal supraventricular tachycardia. Ultrasound Obstet Gynecol 2002; 19:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/28\">",
"      Jouannic JM, Delahaye S, Fermont L, et al. Fetal supraventricular tachycardia: a role for amiodarone as second-line therapy? Prenat Diagn 2003; 23:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/29\">",
"      Ebenroth ES, Cordes TM, Darragh RK. Second-line treatment of fetal supraventricular tachycardia using flecainide acetate. Pediatr Cardiol 2001; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/30\">",
"      Oudijk MA, Michon MM, Kleinman CS, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation 2000; 101:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/31\">",
"      Oudijk MA, Ruskamp JM, Ververs FF, et al. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol 2003; 42:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/32\">",
"      Oudijk MA, Ruskamp JM, Ambachtsheer BE, et al. Drug treatment of fetal tachycardias. Paediatr Drugs 2002; 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/33\">",
"      Etheridge SP, Craig JE, Compton SJ. Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants. Am Heart J 2001; 141:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/34\">",
"      Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation 2011; 124:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/35\">",
"      Grosso S, Berardi R, Cioni M, Morgese G. Transient neonatal hypothyroidism after gestational exposure to amiodarone: a follow-up of two cases. J Endocrinol Invest 1998; 21:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/36\">",
"      Matsumura LK, Born D, Kunii IS, et al. Outcome of thyroid function in newborns from mothers treated with amiodarone. Thyroid 1992; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/37\">",
"      Lomenick JP, Jackson WA, Backeljauw PF. Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol 2004; 24:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/38\">",
"      Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001; 24:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/39\">",
"      Naheed ZJ, Strasburger JF, Deal BJ, et al. Fetal tachycardia: mechanisms and predictors of hydrops fetalis. J Am Coll Cardiol 1996; 27:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/40\">",
"      Moodley S, Sanatani S, Potts JE, Sandor GG. Postnatal outcome in patients with fetal tachycardia. Pediatr Cardiol 2013; 34:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/41\">",
"      Texter KM, Kertesz NJ, Friedman RA, Fenrich AL Jr. Atrial flutter in infants. J Am Coll Cardiol 2006; 48:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/42\">",
"      Lisowski LA, Verheijen PM, Benatar AA, et al. Atrial flutter in the perinatal age group: diagnosis, management and outcome. J Am Coll Cardiol 2000; 35:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/43\">",
"      Simpson JM, Maxwell D, Rosenthal E, Gill H. Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. Ultrasound Obstet Gynecol 2009; 34:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/44\">",
"      Eliasson H, Wahren-Herlenius M, Sonesson SE. Mechanisms in fetal bradyarrhythmia: 65 cases in a single center analyzed by Doppler flow echocardiographic techniques. Ultrasound Obstet Gynecol 2011; 37:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/45\">",
"      Lopes LM, Tavares GM, Damiano AP, et al. Perinatal outcome of fetal atrioventricular block: one-hundred-sixteen cases from a single institution. Circulation 2008; 118:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/46\">",
"      Jaeggi ET, Hornberger LK, Smallhorn JF, Fouron JC. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol 2005; 26:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/47\">",
"      Maeno Y, Himeno W, Saito A, et al. Clinical course of fetal congenital atrioventricular block in the Japanese population: a multicentre experience. Heart 2005; 91:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/48\">",
"      Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/49\">",
"      Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/50\">",
"      Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/51\">",
"      Groves AM, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 1995; 92:3394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/52\">",
"      Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/53\">",
"      Fesslova V, Vignati G, Brucato A, et al. The impact of treatment of the fetus by maternal therapy on the fetal and postnatal outcomes for fetuses diagnosed with isolated complete atrioventricular block. Cardiol Young 2009; 19:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/54\">",
"      Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/55\">",
"      Phoon CK, Kim MY, Buyon JP, Friedman DM. Finding the \"PR-fect\" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease? Congenit Heart Dis 2012; 7:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/56\">",
"      Mivelaz Y, Raboisson MJ, Abadir S, et al. Ultrasonographic diagnosis of delayed atrioventricular conduction during fetal life: a reliability study. Am J Obstet Gynecol 2010; 203:174.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/57\">",
"      Jaeggi ET, Silverman ED, Laskin C, et al. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol 2011; 57:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/58\">",
"      Mevorach D, Elchalal U, Rein AJ. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. Curr Opin Rheumatol 2009; 21:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/59\">",
"      Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/60\">",
"      Breur JM, Visser GH, Kruize AA, et al. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004; 24:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/61\">",
"      Jaeggi ET, Friedberg MK. Diagnosis and management of fetal bradyarrhythmias. Pacing Clin Electrophysiol 2008; 31 Suppl 1:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/62\">",
"      Rosenthal E, Gordon PA, Simpson JM, Sharland GK. Letter regarding article by Jaeggi et al, \"transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease\". Circulation 2005; 111:e287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/63\">",
"      Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/64\">",
"      Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/65\">",
"      Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/66\">",
"      Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/67\">",
"      Tunks RD, Clowse ME, Miller SG, et al. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol 2013; 208:64.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/40/24202/abstract/68\">",
"      Horigome H, Nagashima M, Sumitomo N, et al. Clinical characteristics and genetic background of congenital long-QT syndrome diagnosed in fetal, neonatal, and infantile life: a nationwide questionnaire survey in Japan. Circ Arrhythm Electrophysiol 2010; 3:10.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6765 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24202=[""].join("\n");
var outline_f23_40_24202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Two-dimensional ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      M-mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulsed wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tissue Doppler Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8167751\">",
"      External fetal heart rate monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8167758\">",
"      Fetal magnetocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IRREGULAR RHYTHMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Premature atrial contractions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Premature junctional and ventricular contractions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TACHYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11149956\">",
"      - Approach to management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11149987\">",
"      - Initial maternal and fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11149994\">",
"      - Drug treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2595640\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11150008\">",
"      Flecainide, sotalol, amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11150015\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11150022\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1844638\">",
"      - Clinical vignettes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atrial flutter and fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1844612\">",
"      - Atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Management of atrial flutter and fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11150552\">",
"      Ventricular tachycardia and fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      BRADYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Complete heart block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H646776944\">",
"      - Prevention in fetuses of women with anti-lupus autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nonconducted bigeminy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      2:1 AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6765|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/10/4262\" title=\"figure 1\">",
"      Fetal complete AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/27/25019\" title=\"table 1\">",
"      Frequency fetal arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/33/15900\" title=\"table 2\">",
"      Approach to management of fetal tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43623?source=related_link\">",
"      Irregular heart rate (arrhythmias) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_40_24203="Weight categories";
var content_f23_40_24203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weight categories for adults and youth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adults (20+yrs)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Youth (2 to 19 yrs) CDC, AAP, IOM, ES, IOTF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Underweight",
"       </td>",
"       <td>",
"        BMI &lt;18.5",
"       </td>",
"       <td>",
"        BMI &lt;5th percentile for age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal weight",
"       </td>",
"       <td>",
"        BMI 18.5-24.9",
"       </td>",
"       <td>",
"        BMI &ge;5th to &lt;85th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overweight",
"       </td>",
"       <td>",
"        BMI 25-29.9",
"       </td>",
"       <td>",
"        BMI &ge;85th to &lt;95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"       <td>",
"        BMI &ge;30",
"       </td>",
"       <td>",
"        BMI &ge;95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class III obesity (super obesity)",
"       </td>",
"       <td>",
"        BMI &ge;40",
"       </td>",
"       <td>",
"        Not used*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AAP: American Academy of Pediatrics; IOM: Institute of Medicine; ES: Endocrine society; CDC: Centers for Disease Control; IOTF: International obesity task force; BMI: body mass index.",
"     <br>",
"      * In children, proposed definitions of severe obesity&nbsp;are BMI &gt;120 percent of the 95th percentile, or BMI &gt;99th percentile.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24203=[""].join("\n");
var outline_f23_40_24203=null;
var title_f23_40_24204="Causes of wheeze in children";
var content_f23_40_24204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of wheezing in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Acute",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Asthma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bronchiolitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bronchitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Laryngotracheobronchitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bacterial tracheitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Foreign body aspiration",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Esophageal foreign body",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chronic or recurrent",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          Structural abnormalities",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Tracheo-bronchomalacia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Vascular compression/ rings",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Tracheal stenosis/webs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Cystic lesions/masses",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Tumors/lymphadenopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Cardiomegaly",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          Functional abnormalities",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Asthma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Gastroesophageal reflux",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Recurrent aspiration",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Cystic fibrosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Immunodeficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Primary ciliary dyskinesia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Bronchopulmonary dysplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Retained foreign body (trachea or esophagus)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Bronchiolitis obliterans",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Pulmonary edema",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Vocal cord dysfunction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          Interstitial lung disease",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24204=[""].join("\n");
var outline_f23_40_24204=null;
var title_f23_40_24205="Survival with arterial versus venous aortocoronary grafts";
var content_f23_40_24205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival with arterial versus venous aortocoronary grafts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with three-vessel coronary artery disease, survival is better when the internal mammary artery was used as compared to the use of only vein grafts",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Loop FD, Lytle BW, Cosgrove DM, et al. N Engl J Med 1986; 314:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24205=[""].join("\n");
var outline_f23_40_24205=null;
var title_f23_40_24206="Reverse transcriptase PCR";
var content_f23_40_24206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reverse-transcriptase polymerase chain reaction (RT-PCR)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The reverse-transcription polyermase chain reaction (PCR) assay works as follows: within target cells, genomic DNA (top) is naturally transcribed into messenger RNA (mRNA); this can be subsequently isolated using a variety of techniques. mRNA is then converted into complementary DNA (cDNA) by an RNA- dependent DNA polymerase, termed reverse transcriptase. Next, the cDNA is changed into double-stranded DNA, becoming the template for a subsequent PCR reaction. After the amplification reaction, the product can be visualized by gel electrophoresis (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24206=[""].join("\n");
var outline_f23_40_24206=null;
var title_f23_40_24207="MPS I forearm";
var content_f23_40_24207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Radiograph of the arm in a patient with mucopolysaccharidosis type I (MPS I)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical features of bone disease include tilting of the radius and ulna distal epiphyses (arrow 1) and abnormal tubulation of the long bones, leading to the arching shape of the radius (arrow 2).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_40_24207=[""].join("\n");
var outline_f23_40_24207=null;
